

PYRIMIDINE DERIVATIVES

This invention relates to pyrimidine derivatives and to processes for the preparation of, compositions
5 containing and the uses of, such derivatives.

The pyrimidine derivatives of the present invention are histamine H₄ receptor ligands and have therefore
a number of therapeutic applications, particularly in the treatment of asthma, allergic rhinitis, chronic
obstructive pulmonary disorder (COPD) and histamine-mediated inflammatory diseases.


10

The histamine H₄ receptor is a 390 amino-acid, seven-transmembrane G protein coupled receptor with
approximately 40 % homology to the histamine H₃ receptor. In contrast to the H₃ receptor, which is
primarily located in the brain, the H₄ receptor is expressed at greater levels in eosinophils and mast cells,
among other inflammatory cells. H₄ receptor ligands should thus be suitable for the treatment of various
15 inflammatory disorders. Examples of diseases where treatment with H₄ ligands is particularly appropriate
are inflammatory bowel disease, Crohn's disease, colitis ulcerosa, dermatitis, psoriasis, conjunctivitis,
rheumatoid arthritis, respiratory diseases such as adult respiratory distress syndrome, acute respiratory
distress syndrome, bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis,
asthma, emphysema, rhinitis, chronic sinusitis, allergy, allergy-induced airway responses, allergic rhinitis,
20 viral rhinitis, non-allergic rhinitis, perennial and seasonal rhinitis, nasal congestion and allergic
congestion.

Recently some histamine H₄ receptor ligands have been developed. An overview of the current advance
in H₄ ligand research and patenting is given in *Expert Opin. Ther. Patents* (2003) 13(6). Examples of
25 Histamine H₄ receptor ligands can be found in WO 02/072548, WO 04/022537 and in Terzioglu et al., *J.*
Bioorg. Med. Chem. Lett. 14 (2004), 5251-5256.

Although H₄ ligands are known there is still a need to further provide new H₄ ligands that are good drug
candidates. In particular, preferred compounds should bind potently to the histamine H₄ receptor whilst
30 showing little affinity for other receptors. They should be well absorbed from the gastrointestinal tract, be
metabolically stable and possess favourable pharmacokinetic properties. They should be non-toxic and
demonstrate few side-effects.

The present invention thus relates to pyrimidine derivatives of formula (I):



35

or a pharmaceutically and/or veterinarily acceptable derivative thereof, wherein:

R^1 is C_{1-8} alkyl, C_{3-7} cycloalkyl- C_{0-6} alkyl- optionally substituted with methyl, alkoxyalkyl containing 3 to 8 carbon atoms, het- C_{0-6} alkyl-, CF_3 - C_{1-6} alkyl-, CF_3OC_{2-3} alkyl-, aryl- C_{0-6} alkyl- or C_{1-6} hydroxyalkyl;

R^2 is het, provided that the het group contains at least one nitrogen atom or is substituted by a group which contains at least one nitrogen atom; or R^2 is $(CH_2)_2NH_2$, $(CH_2)_2NHCH_3$, or $(CH_2)_2$ $(CH_3)_2$,

R^3 is H, C_{1-6} alkyl, $(CH_2)_pC_{3-7}$ cycloalkyl, alkoxyalkyl containing 3 to 8 carbon atoms, $(CH_2)_nCF_3$, $(CH_2)_xOCF_3$ or C_{1-6} hydroxyalkyl; or R^3 and R^2 together with the nitrogen atom to which they are bound form a 4 to 8 membered non-aromatic heterocyclic group which optionally contains one or more further heteroatoms or groups independently selected from N, O, S, S(O) and S(O)₂, wherein the heterocyclic group is optionally a bridged bicyclic group, a spiro bicyclic group or is optionally fused to a 3-, 4-, 5- or 6-membered carbocyclic group or a 4-, 5- or 6-membered heterocyclic group which contains at least one ring member independently selected from N, O, S, S(O) and S(O)₂, and wherein the ring system as a whole is optionally substituted by one or more substituents independently selected from C_{1-6} alkyl, NR^6R^7 , $(CH_2)_aC_{3-7}$ cycloalkyl, alkoxyalkyl containing 2 to 8 carbon atoms, $(CH_2)_b$ het¹, $(CH_2)_cCF_3$, $(CH_2)_yOCF_3$, $(CH_2)_d$ aryl and C_{1-6} hydroxyalkyl, provided that the ring system as a whole contains at least two nitrogen atoms or contains one nitrogen atom and is substituted by a group which contains at least one nitrogen atom;

R^4 is H; or R^1 and R^4 together with the nitrogen atom to which they are bound form a 4 to 8 membered non-aromatic heterocyclic group which optionally contains one or more further heteroatoms or groups independently selected from N, O, S, S(O) and S(O)₂, wherein the heterocyclic group is optionally a bridged bicyclic group or is optionally fused to a 3-, 4-, 5- or 6-membered carbocyclic group or a 4-, 5- or 6-membered heterocyclic group which contains at least one ring member independently selected from N, O, S, S(O) and S(O)₂, and wherein the ring system as a whole is optionally substituted by one or more substituents independently selected from C_{1-6} alkyl, fluoro, NR^9R^{10} , $(CH_2)_eC_{3-7}$ cycloalkyl, alkoxyalkyl containing 2 to 8 carbon atoms, $(CH_2)_f$ het¹, $(CH_2)_gCF_3$, $(CH_2)_zOCF_3$, $(CH_2)_h$ aryl and C_{1-6} hydroxyalkyl;

R^5 is H or $NR^{11}R^{12}$;

R^6 and R^7 are each independently selected from H, C_{1-6} alkyl and $(CH_2)_iC_{3-7}$ cycloalkyl; or R^6 and R^7 , together with the nitrogen atom to which they are bound, form a 4, 5 or 6 membered heterocyclic group;

R^8 is H or C_{1-3} alkyl;

R^9 and R^{10} are each independently selected from H, C_{1-6} alkyl and $(CH_2)_kC_{3-7}$ cycloalkyl; or R^9 and R^{10} , together with the nitrogen atom to which they are bound, form a 4, 5 or 6 membered heterocyclic group;

R^{11} and R^{12} are each independently selected from H, C_{1-6} alkyl and $(CH_2)_lC_{3-7}$ cycloalkyl; or R^{11} and R^{12} , together with the nitrogen atom to which they are bound, form a 4, 5 or 6 membered heterocyclic group;

R^{13} and R^{14} are each independently selected from H, C_{1-6} alkyl and $(CH_2)_mC_{3-7}$ cycloalkyl; or R^{13} and R^{14} , together with the nitrogen atom to which they are bound, form a 4, 5 or 6 membered heterocyclic group;

a, b, c, d, e, f, g, h, j, k, l, m and p are each independently selected from 0, 1, 2 and 3;

n is 1, 2 or 3;

x is 2 or 3, wherein if x is 3, then the $(CH_2)_3$ group may be replaced with a branched alkyl group containing 3 carbon atoms;

y and z are each independently selected from 1, 2 and 3

aryl is phenyl, naphthyl, anthracyl or phenanthryl, each optionally substituted by one or more groups independently selected from C₁₋₈alkyl, C₁₋₈alkoxy, OH, halo, CF₃, CHF₂, OCF₃, OCHF₂, SCF₃, hydroxy-C₁₋₆alkyl, C₁₋₄alkoxy-C₁₋₆alkyl, C₁₋₄alkyl-S-C₁₋₄alkyl, aryl¹, het¹, Oaryl¹, Ohet¹, Saryl¹, Shet¹, CF₂CF₃, CH₂CF₃, CF₂CH₃, C(O)NR¹³R¹⁴, C₃₋₈cycloalkyl, C₃₋₇cycloalkyl-C₁₋₄alkyl, C₃₋₇cycloalkyl-C₁₋₄alkoxy, C₃₋₇cycloalkyl-O-C₁₋₄alkyl, C₃₋₇cycloalkyl-C₁₋₄alkoxy-C₁₋₄alkyl, OC₃₋₇cycloalkyl and SC₃₋₇cycloalkyl, wherein the aryl¹ and het¹ groups are optionally substituted by at least one group selected from C₁₋₆alkyl, C₃₋₇cycloalkyl, C₁₋₆alkoxy, OC₃₋₇cycloalkyl, halo, CN, OH, CF₃, CHF₂, OCF₃, OCHF₂, hydroxyC₁₋₆alkyl, C₁₋₄alkoxy-C₁₋₄alkyl, SC₁₋₆alkyl and SCF₃;

het is 4 to 8 membered non-aromatic heterocyclic group which contains at least one heteroatom or group independently selected from N, O, S, S(O) and S(O)₂, wherein the heterocyclic group is optionally a bridged bicyclic group or is optionally fused to a 3-, 4-, 5- or 6- membered carbocyclic group or a 4-, 5- or 6-membered heterocyclic group which contains at least one ring member independently selected from N, O, S, S(O) and S(O)₂, and wherein the ring system as a whole is optionally substituted by one or more substituents independently selected from C₁₋₆alkyl, NR⁶R⁷, (CH₂)_aC₃₋₇cycloalkyl, alkoxyalkyl containing 2 to 8 carbon atoms, (CH₂)_bhet¹, (CH₂)_cCF₃, (CH₂)_yOCF₃, (CH₂)_daryl and C₁₋₆hydroxyalkyl;

aryl¹ is phenyl, naphthyl, anthracyl or phenanthryl; and

het¹ is an aromatic or non-aromatic 4-, 5- or 6- membered heterocycle which contains at least one N, O or S heteroatom, optionally fused to a 4-, 5- or 6- membered carbocyclic group or a second 4-, 5- or 6-membered heterocycle which contains at least one N, O or S heteroatom.

Preferably aryl is phenyl.

For embodiments in which the groups "aryl", "aryl¹", "het" and "het¹" may be a substituent on more than one part of the compound, it is to be understood that each separate substituent may be the same or different to the other substituent(s) defined by the same term. For example, if R¹ and R² both comprise a "het" group, then the two het groups may be the same or different.

It has been found that the compounds defined above are ligands of the Histamine H₄ receptor.

In an embodiment of the invention R¹, R², R³, R⁴ and R⁵ are as defined above, and R⁸ is hydrogen.

In a further embodiment, R¹, R², R³, R⁵ and R⁸ are as defined above, and R⁴ is hydrogen.

In a further embodiment, R², R³, R⁵ and R⁸ are as defined above, R⁴ is hydrogen and R¹ is C₃₋₇cycloalkyl-C₀₋₆alkyl- optionally substituted with methyl.

In a further embodiment, R², R³, R⁵ and R⁸ are as defined above, R⁴ is hydrogen and R¹ is C₃₋₅cycloalkyl-C₀₋₁alkyl- optionally substituted with methyl.

In a further embodiment, R², R³, R⁵ and R⁸ are as defined above, R⁴ is hydrogen and R¹ is cyclopropyl, cyclopropyl-methyl or methyl-cyclopropyl.

In a further embodiment, R², R³, R⁵ and R⁸ are as defined above, R⁴ is hydrogen and R¹ is C₁₋₈ alkyl.

In a further embodiment, R², R³, R⁵ and R⁸ are as defined above, R⁴ is hydrogen and R¹ is C₁₋₆ alkyl.

In a further embodiment, R², R³, R⁵ and R⁸ are as defined above, R⁴ is hydrogen and R¹ is ethyl, propyl, butyl, 1-methyl-propyl, 2-methyl-propyl, 2,2-dimethyl-propyl, 2-methyl-butyl, ter-butyl, 1-methyl-butyl, 3-methyl-butyl, 3,3-dimethyl-butyl, 1,2-dimethyl-propyl or isopropyl.

In a further embodiment, R^1 , R^4 , R^5 and R^8 are as defined above, and R^2 is het, provided that the het group contains at least one nitrogen atom or is substituted by a group which contains at least one nitrogen atom and R^3 is H, C_{1-6} alkyl, $(CH_2)_pC_{3-7}$ cycloalkyl, alkoxyalkyl containing 3 to 8 carbon atoms, $(CH_2)_nCF_3$, $(CH_2)_xOCF_3$ or C_{1-6} hydroxyalkyl; or R^3 and R^2 together with the nitrogen atom to which they are bound form a 4 to 8 membered non-aromatic heterocyclic group which optionally contains one or more further heteroatoms or groups independently selected from N, O, S, S(O) and $S(O)_2$, wherein the heterocyclic group is optionally a bridged bicyclic group, a spiro bicyclic group or is optionally fused to a 3-, 4-, 5- or 6- membered carbocyclic group or a 4-, 5- or 6-membered heterocyclic group which contains at least one ring member independently selected from N, O, S, S(O) and $S(O)_2$, and wherein the ring system as a whole is optionally substituted by one or more substituents independently selected from C_{1-6} alkyl, NR^6R^7 , $(CH_2)_aC_{3-7}$ cycloalkyl, alkoxyalkyl containing 2 to 8 carbon atoms, $(CH_2)_bhet^1$, $(CH_2)_cCF_3$, $(CH_2)_yOCF_3$, $(CH_2)_daryl$ and C_{1-6} hydroxyalkyl, provided that the ring system as a whole contains at least two nitrogen atoms or contains one nitrogen atom and is substituted by a group which contains at least one nitrogen atom;


In a still further embodiment, R^1 , R^4 , R^5 and R^8 are as defined above, and R^2 and R^3 , together with the nitrogen atom to which they are bound, form a 4 to 8 membered non-aromatic heterocyclic group which optionally contains one or more further heteroatoms or groups independently selected from N, O, S, S(O) and $S(O)_2$, wherein the heterocyclic group is optionally a bridged bicyclic group or is optionally fused to a 3-, 4-, 5- or 6- membered carbocyclic group or a 4-, 5- or 6-membered heterocyclic group which contains at least one ring member independently selected from N, O, S, S(O) and $S(O)_2$, and wherein the ring system as a whole is optionally substituted by one or more substituents independently selected from C_{1-6} alkyl, NR^6R^7 , $(CH_2)_aC_{3-7}$ cycloalkyl, alkoxyalkyl containing 2 to 8 carbon atoms, $(CH_2)_bhet^1$, $(CH_2)_cCF_3$, $(CH_2)_yOCF_3$, $(CH_2)_daryl$ and C_{1-6} hydroxyalkyl, provided that the ring system as a whole contains at least two nitrogen atoms or contains one nitrogen atom and is substituted by a group which contains at least one nitrogen atom.

In a further embodiment, R^1 , R^4 , R^5 and R^8 are as defined above, and R^2 and R^3 , together with the nitrogen atom to which they are bound, form a 4 to 8 membered non-aromatic heterocyclic group which optionally contains one or more further nitrogen atoms, wherein the heterocyclic group is optionally a bridged bicyclic group or is optionally fused to a 3-, 4-, 5- or 6- membered carbocyclic group or a 4-, 5- or 6-membered heterocyclic group which contains at least one nitrogen atom, and wherein the ring system as a whole is optionally substituted by one or more substituents independently selected from C_{1-6} alkyl, NR^6R^7 , $(CH_2)_aC_{3-7}$ cycloalkyl, alkoxyalkyl containing 2 to 8 carbon atoms, $(CH_2)_bhet^1$, $(CH_2)_cCF_3$, $(CH_2)_yOCF_3$, $(CH_2)_daryl$ and C_{1-6} hydroxyalkyl, provided that the ring system as a whole contains at least two nitrogen atoms or contains one nitrogen atom and is substituted by a group which contains at least one nitrogen atom.

In a yet still further embodiment, R^1 , R^4 , R^5 and R^8 are as defined above, and R^2 is $(CH_2)_2NH_2$, $(CH_2)_2NHCH_3$, $(CH_2)_2$, $(CH_3)_2$ and R^3 is H.


In a yet still further embodiment, R^1 , R^4 , R^5 and R^8 are as defined above, and R^2 and R^3 , together with the nitrogen atom to which they are bound, form a 4 to 8 membered non-aromatic heterocyclic group selected from the following ring systems:

5



wherein the ring system as a whole may be substituted by one or more C_{1-6} alkyl or $(CH_2)_aC_{3-6}$ cycloalkyl groups.

- 10 In a yet still further embodiment, R^1 , R^4 , R^5 and R^8 are as defined above, and R^2 and R^3 , together with the nitrogen atom to which they are bound, form a 4 to 8 membered non-aromatic heterocyclic group selected from the following ring systems:



wherein R^6 and R^7 are independently selected from H or CH_3 .

In a further embodiment, R^1 , R^4 , R^5 and R^8 are as defined above, R^3 is H and R^2 is a pyrrolidinyl group, optionally substituted by one or more substituents independently selected from C_{1-6} alkyl, NR^6R^7 , $(\text{CH}_2)_a\text{C}_{3-7}$ cycloalkyl, alkoxyalkyl containing 2 to 8 carbon atoms, $(\text{CH}_2)_b\text{het}^1$, $(\text{CH}_2)_c\text{CF}_3$, $(\text{CH}_2)_y\text{OCF}_3$, $(\text{CH}_2)_d\text{aryl}$ and C_{1-6} hydroxyalkyl.

In a further embodiment, R^1 , R^4 , R^5 and R^8 are as defined above, R^3 is H and R^2 is a pyrrolidinyl group, optionally substituted by one or more substituents independently selected from C_{1-6} alkyl, NR^6R^7 , $(\text{CH}_2)_a\text{C}_{3-7}$ cycloalkyl and alkoxyalkyl containing 2 to 8 carbon atoms.

In a further embodiment, R^1 , R^2 , R^3 , R^4 and R^8 are as defined above, and R^5 is H or NH_2 .

In the here above formula "halo" denotes a halogen atom selected from the group consisting of fluoro, chloro, bromo and iodo, in particular fluoro or chloro.

- The term "alkyl" includes both straight-chain and branched chain groups. This also applies if they carry substituents such as a hydroxy substituent or occur as substituents of other radicals, for example alkoxy groups. For example, the term C₁₋₄alkyl includes methyl, ethyl, *n*-propyl, *iso*-propyl, *n*-butyl, *iso*-butyl, *sec*-butyl and *tert*-butyl moieties. Examples of the corresponding alkoxy moieties are methoxy, ethoxy, *n*-propyloxy, *iso*-propyloxy, *n*-butoxy, *iso*-butoxy, *sec*-butoxy and *tert*-butoxy. Furthermore, examples of suitable C₁₋₄alkyl moieties substituted by an hydroxyl group are hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-hydroxypropyl, 2-hydroxypropyl, 3-hydroxypropyl, etc.
- The term C₃-C₇ cycloalkyl includes bridged bicyclic cycloalkyl such as bicyclo[1.1.1]pentyl. Preferred cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and bicyclo[1.1.1]pentyl.

Preferred "4 to 8 membered heterocyclic group which optionally contains one or more further heteroatoms or groups independently selected from N, O, S, S(O) and S(O)₂, wherein the heterocyclic group is a spiro bicyclic group" are 2,8-diaza-spiro[4.5]dec-2-yl and 2,7-diaza-spiro[4.4]non-2-yl.

- The skilled person will of course appreciate that it is not possible to substitute some of the defined heterocyclic ring groups of Formula I in all positions with some of the optional substituents defined above. It is to be understood that such substitutions do not form part of the invention.

- Example compounds that fall within the above definition of the invention include:
- N*-(3,3-Dimethylbutyl)-6-(4-methylpiperazin-1-yl)pyrimidin-4-amine,
 6-[3-(Dimethylamino)pyrrolidin-1-yl]-*N*-(3,3-dimethylbutyl)pyrimidin-4-amine,
N-(3,3-Dimethylbutyl)-6-[(5-methylhexahydropyrrolo[3,4-*c*]pyrrol-2(1H)-yl]pyrimidin-4-amine,
 6-[3-(Dimethylamino)azetidin-1-yl]-*N*-(3,3-dimethylbutyl)pyrimidin-4-amine,
N-(3,3-Dimethylbutyl)-6-[5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]pyrimidin-4-amine,
N-(3,3-Dimethylbutyl)-*N'*-[pyrrolidin-3-yl]pyrimidine-4,6-diamine,
N-(3,3-Dimethylbutyl)-*N'*-[1-methylpyrrolidin-3-yl]pyrimidine-4,6-diamine,
N'-(Cyclopropylmethyl)-6-[3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine,
N'-Isobutyl-6-[3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine,
N'-(2,2-Dimethylpropyl)-6-[3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine,
N'-Ethyl-6-[3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine,
N-Ethyl-6-[3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine,
N-Isobutyl-6-[3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine,
N-(Cyclopropylmethyl)-6-[3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine,
N-(3,3-Dimethylbutyl)-6-[3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine,
 6-[3-(Dimethylamino)pyrrolidin-1-yl]-*N*-(3,3-dimethylbutyl)pyrimidin-4-amine,
N-(Cyclopropylmethyl)-6-[3-(dimethylamino)pyrrolidin-1-yl]pyrimidin-4-amine,
 6-[3-(Dimethylamino)pyrrolidin-1-yl]-*N*-isobutylpyrimidin-4-amine,
 6-[3-(Dimethylamino)pyrrolidin-1-yl]-*N*-ethylpyrimidin-4-amine,

- 6-[3-(Dimethylamino)pyrrolidin-1-yl]-*N*-(2,2-dimethylpropyl)pyrimidin-4-amine,
*N*⁴-(3,3-Dimethylbutyl)-6-[octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine,
*N*⁴-Isopropyl-6-[octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine,
*N*⁴-Methyl-6-[octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine,
5 *N*⁴-Ethyl-6-[octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine,
*N*⁴-Isobutyl-6-[octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine,
*N*⁴-(Cyclopropylmethyl)-6-[octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine,
*N*⁴-(3-Methylbutyl)-6-[octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine,
*N*⁴-(2,2-Dimethylpropyl)-6-[octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine,
10 *N*⁴-Cyclopropyl-6-[octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine,
*N*⁴-Cyclobutyl-6-[octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine,
*N*⁴-(Cyclopentylmethyl)-6-[octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine,
6-[5-Methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-*N*⁴-propylpyrimidine-2,4-diamine,
*N*⁴-Methyl-6-[5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]pyrimidine-2,4-diamine,
15 *N*⁴-Ethyl-6-[5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]pyrimidine-2,4-diamine,
*N*⁴-Isobutyl-6-[5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]pyrimidine-2,4-diamine,
*N*⁴-(Cyclopropylmethyl)-6-[5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]pyrimidine-2,4-diamine,
*N*⁴-(2,2-Dimethylpropyl)-6-[5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]pyrimidine-2,4-diamine,
*N*⁴-(3,3-Dimethylbutyl)-6-[5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]pyrimidine-2,4-diamine,
20 *N*⁴-(3-Methylbutyl)-6-[5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]pyrimidine-2,4-diamine,
*N*⁴-Cyclopropyl-6-[5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]pyrimidine-2,4-diamine,
*N*⁴-Cyclobutyl-6-[5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]pyrimidine-2,4-diamine,
Cyclopropylmethyl-6-[3-(methylamino)azetidin-1-yl]-pyrimidin-4-yl]-amine,
(3-Fluoro-benzyl)-[6-(3-methylamino)azetidin-1-yl]-pyrimidin-4-yl]-amine,
25 *N*-Isopropyl-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine,
N-(4-Fluorobenzyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine,
N-Ethyl-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine,
N-Isobutyl-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine,
2-({6-[3-(Methylamino)azetidin-1-yl]pyrimidin-4-yl}amino)ethanol,
30 *N*-Benzyl-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine,
N-(2-Chlorobenzyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine,
N-Methyl-1-[6-(4-methylpiperidin-1-yl)pyrimidin-4-yl]azetidin-3-amine,
N-(2-Methoxyethyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine,
6-[3-(Methylamino)azetidin-1-yl]-*N*-(3-methylbutyl)pyrimidin-4-amine,
35 *N*-Methyl-1-(6-piperidin-1-ylpyrimidin-4-yl)azetidin-3-amine,
N-(2,2-Dimethylpropyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine,
N-Methyl-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine,
N-(3,3-Dimethylbutyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine,
*N*⁴-Isopropyl-6-(3-methylamino)azetidin-1-yl-pyrimidine-2,4-diamine,
40 *N*⁴-(2,2-Dimethylpropyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine,
6-(3-Methylamino)azetidin-1-yl)-*N*⁴-(3,3,3-trifluoro-propyl)-pyrimidine-2,4-diamine,

- N*⁴-Cyclopropylmethyl-6-(3-methylamino-azetidin-1-yl)-pyrimidine-2,4-diamine,
*N*⁴-(3,3-Dimethyl-butyl)-6-(3-methylamino-azetidin-1-yl)-pyrimidine-2,4-diamine,
*N*⁴-(3-Fluoro-benzyl)-6-(3-methylamino-azetidin-1-yl)-pyrimidine-2,4-diamine,
*N*⁴-(3-Methoxy-benzyl)-6-(3-methylamino-azetidin-1-yl)-pyrimidine-2,4-diamine,
5 *N*⁴-Cyclobutylmethyl-6-(3-methylamino-azetidin-1-yl)-pyrimidine-2,4-diamine,
*N*⁴-Cyclopentylmethyl-6-(3-methylamino-azetidin-1-yl)-pyrimidine-2,4-diamine,
*N*⁴-Methyl-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine,
*N*⁴-Ethyl-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine,
*N*⁴-Isobutyl-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine,
10 *N*⁴-Cyclopropyl-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine,
6-[3-(Methylamino)azetidin-1-yl]-*N*⁴-propylpyrimidine-2,4-diamine,
6-[3-(Methylamino)azetidin-1-yl]-*N*⁴-(3-methylbutyl)pyrimidine-2,4-diamine,
*N*⁴-Cyclobutyl-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine,
6-[3-(Methylamino)azetidin-1-yl]-*N*⁴-[4-(trifluoromethoxy)benzyl]pyrimidine-2,4-diamine,
15 4-[[2-Amino-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-yl]amino)methyl]benzonitrile,
*N*⁴-(2-Fluorobenzyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine,
*N*⁴-Benzyl-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine,
6-[3-(Methylamino)azetidin-1-yl]-*N*⁴-[3-(trifluoromethyl)benzyl]pyrimidine-2,4-diamine,
*N*⁴-(4-Chlorobenzyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine,
20 6-[3-(Methylamino)azetidin-1-yl]-*N*⁴-(2-methylbenzyl)pyrimidine-2,4-diamine,
6-[3-(Methylamino)azetidin-1-yl]-*N*⁴-(3-methylbenzyl)pyrimidine-2,4-diamine,
6-[3-(Methylamino)azetidin-1-yl]-*N*⁴-[2-(trifluoromethyl)benzyl]pyrimidine-2,4-diamine,
6-[3-(Methylamino)azetidin-1-yl]-*N*⁴-[4-(trifluoromethyl)benzyl]pyrimidine-2,4-diamine,
*N*⁴-(3-Chlorobenzyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine,
25 *N*⁴-(2-Methoxybenzyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine,
6-[3-(Methylamino)azetidin-1-yl]-*N*⁴-(4-methylbenzyl)pyrimidine-2,4-diamine,
*N*⁴-(2-Chlorobenzyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine,
*N*⁴-(4-Fluorobenzyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine,
*N*⁴-(3-Fluorobenzyl)-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine,
30 *N*⁴-(3-Fluorobenzyl)-6-[5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]pyrimidine-2,4-diamine,
*N*⁴-(3,3-Dimethylbutyl)-6-[3-methylpiperazin-1-yl]pyrimidine-2,4-diamine,
*N*⁴-(2,2-Dimethylpropyl)-6-[3-methylpiperazin-1-yl]pyrimidine-2,4-diamine,
*N*⁴-Ethyl-6-[3-methylpiperazin-1-yl]pyrimidine-2,4-diamine,
N-(2,2-Dimethylpropyl)-6-(4-methylpiperazin-1-yl)pyrimidin-4-amine,
35 *N*-(3-Methylbutyl)-6-(4-methylpiperazin-1-yl)pyrimidin-4-amine,
*N*⁴-(3,3-Dimethylbutyl)-*N*⁶-[pyrrolidin-3-yl]pyrimidine-2,4,6-triamine,
*N*⁴-(3,3-Dimethylbutyl)-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine,
N-Ethyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-amine,
N-Isopropyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-amine,
40 *N*-Isobutyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-amine,
N-(Cyclopropylmethyl)-6-(4-methylpiperazin-1-yl)pyrimidin-4-amine,

- N*-(3-Methylbutyl)-*N'*-[pyrrolidin-3-yl]pyrimidine-4,6-diamine,
*N*⁴-(3-Methylbutyl)-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine,
N-(2-Methoxyethyl)-6-(4-methylpiperazin-1-yl)pyrimidin-4-amine,
N-(3,3-Dimethylbutyl)-6-piperazin-1-ylpyrimidin-4-amine,
5 6-(4-Methylpiperazin-1-yl)-*N*-[tetrahydrofuran-2-ylmethyl]pyrimidin-4-amine,
4-(4-Methylpiperazin-1-yl)-6-pyrrolidin-1-ylpyrimidine,
6-(4-Methylpiperazin-1-yl)-*N*-(3,3,3-trifluoropropyl)pyrimidin-4-amine,
N-Isobutyl-5-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-amine,
N-Ethyl-6-[5-methylhexahydropyrrolo[3,4-*c*]pyrrol-2(1*H*)-yl]pyrimidin-4-amine,
10 6-(3-Aminoazetidin-1-yl)-*N*-(3,3-dimethylbutyl)pyrimidin-4-amine,
*N*⁴-Isopropyl-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine,
*N*⁴-Ethyl-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine,
*N*⁴-Isobutyl-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine,
*N*⁴-(Cyclopropylmethyl)-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine,
15 *N*-(Cyclopropylmethyl)-6-[octahydro-6*H*-pyrrolo[3,4-*b*]pyridin-6-yl]pyrimidin-4-amine,
*N*⁴-(3,3-Dimethylbutyl)-6-[3,4-dimethylpiperazin-1-yl]pyrimidine-2,4-diamine,
N-Isobutyl-6-[octahydro-6*H*-pyrrolo[3,4-*b*]pyridin-6-yl]pyrimidin-4-amine,
6-[6-Amino-3-azabicyclo[3.1.0]hex-3-yl]-*N*⁴-(2,2-dimethylpropyl)pyrimidine-2,4-diamine,
N-(2,2-Dimethylpropyl)-6-[octahydro-6*H*-pyrrolo[3,4-*b*]pyridin-6-yl]pyrimidin-4-amine,
20 6-[3-(Methylamino)azetidin-1-yl]-*N*⁴-(2-methylbutyl)pyrimidine-2,4-diamine,
*N*⁴-[(1*S*)-1,2-Dimethylpropyl]-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine,
*N*⁴-(2,5-Difluorobenzyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine,
*N*⁴-(2,3-Difluorobenzyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine,
*N*⁴-Butyl-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine,
25 6-(1,4-Diazepan-1-yl)-*N*⁴-isobutylpyrimidine-2,4-diamine,
6-[(3*R*)-3-(Methylamino)pyrrolidin-1-yl]-*N*⁴-(2-methylcyclopropyl)pyrimidine-2,4-diamine,
*N*⁴-Isobutyl-6-(4-methyl-1,4-diazepan-1-yl)pyrimidine-2,4-diamine,
*N*⁴-(Cyclopropylmethyl)-6-(3-pyrrolidin-1-ylazetidin-1-yl)pyrimidine-2,4-diamine,
*N*⁴-Isopropyl-6-[(3*aR**,7*aS**)-octahydro-5*H*-pyrrolo[3,2-*c*]pyridin-5-yl]pyrimidine-2,4-diamine,
30 *N*⁴-Bicyclo[1.1.1]pent-1-yl-6-[(3*R*)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine,
6-(4-Aminopiperidin-1-yl)-*N*⁴-ethylpyrimidine-2,4-diamine,
6-[3-Methyl-3-(methylamino)azetidin-1-yl]-*N*⁴-propylpyrimidine-2,4-diamine,
*N*⁴-(2,2-Dimethylpropyl)-6-(hexahydropyrrolo[1,2-*a*]pyrazin-2(1*H*)-yl)pyrimidine-2,4-diamine,
*N*⁴-(2,2-Dimethylpropyl)-6-(3-pyrrolidin-1-ylazetidin-1-yl)pyrimidine-2,4-diamine,
35 *N*⁴-(2,2-Dimethylpropyl)-*N*⁶-[2-(methylamino)ethyl]pyrimidine-2,4,6-triamine,
*N*⁴-[2-(Dimethylamino)ethyl]-*N*⁶-(2,2-dimethylpropyl)pyrimidine-2,4,6-triamine,
*N*⁴-(2,2-Dimethylpropyl)-6-[3-(isopropylamino)azetidin-1-yl]pyrimidine-2,4-diamine,
6-[(3*R*)-3-(Methylamino)pyrrolidin-1-yl]-*N*-[(1*R*)-1-methylpropyl]pyrimidin-4-amine,
N-Butyl-6-[(3*R*)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine,
40 *N*⁴-(*tert*-Butyl)-6-[(3*R*)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine,
6-[(3*R*)-3-(Methylamino)pyrrolidin-1-yl]-*N*⁴-(1-methylcyclopropyl)pyrimidine-2,4-diamine,

N^4 -(*tert*-Butyl)-6-[(4aS*,7aS*)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine,
 6-[(3R)-3-(Methylamino)pyrrolidin-1-yl]- N^4 -[(1S)-1-methylpropyl]pyrimidine-2,4-diamine,
 6-[(3R)-3-(Methylamino)pyrrolidin-1-yl]- N^4 -[(1R)-1-methylpropyl]pyrimidine-2,4-diamine, and,
 N-(*sec*-Butyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine,

5 or a pharmaceutically and/or veterinarily acceptable derivative thereof.

An embodiment of the invention provides the following compounds:

- N^4 -(Cyclopropylmethyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine,
 N^4 -(Cyclopropylmethyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine tartrate,
 10 N^4 -Isobutyl-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine,
 N^4 -(2,2-Dimethylpropyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine,
 N-Isobutyl-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine,
 N-(Cyclopropylmethyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine,
 N^4 -(2,2-Dimethylpropyl)-6-[(4aR*,7aR*)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine,
 15 N^4 -Cyclopropyl-6-[(4aR*,7aR*)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine,
 N^4 -Cyclobutyl-6-[(4aR*,7aR*)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine,
 N^4 -(2,2-Dimethylpropyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine,
 6-(3-Methylamino-azetidin-1-yl)- N^4 -(3,3,3-trifluoro-propyl)-pyrimidine-2,4-diamine,
 N^4 -Cyclopropylmethyl-6-(3-methylamino-azetidin-1-yl)-pyrimidine-2,4-diamine,
 20 N^4 -(3,3-Dimethyl-butyl)-6-(3-methylamino-azetidin-1-yl)-pyrimidine-2,4-diamine,
 N^4 -(3-Fluoro-benzyl)-6-(3-methylamino-azetidin-1-yl)-pyrimidine-2,4-diamine,
 N^4 -Cyclopentylmethyl-6-(3-methylamino-azetidin-1-yl)-pyrimidine-2,4-diamine,
 N^4 -Isobutyl-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine,
 6-[3-(Methylamino)azetidin-1-yl]- N^4 -propylpyrimidine-2,4-diamine,
 25 N^4 -(2-Methoxybenzyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine,
 N^4 -(2,2-Dimethylpropyl)-6-[(3R)-3-methylpiperazin-1-yl]pyrimidine-2,4-diamine,
 N^4 -Ethyl-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine,
 N^4 -(Cyclopropylmethyl)-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine,
 6-[3-(Methylamino)azetidin-1-yl]- N^4 -(2-methylbutyl)pyrimidine-2,4-diamine,
 30 N^4 -(2,5-Difluorobenzyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine,
 N^4 -(2,3-Difluorobenzyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine,
 N^4 -Butyl-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine,
 6-[(3R)-3-(Methylamino)pyrrolidin-1-yl]- N^4 -(2-methylcyclopropyl)pyrimidine-2,4-diamine,
 N^4 -Isobutyl-6-(4-methyl-1,4-diazepan-1-yl)pyrimidine-2,4-diamine,
 35 N^4 -(Cyclopropylmethyl)-6-(3-pyrrolidin-1-ylazetidin-1-yl)pyrimidine-2,4-diamine,
 N^4 -Bicyclo[1.1.1]pent-1-yl-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine,
 6-[3-Methyl-3-(methylamino)azetidin-1-yl]- N^4 -propylpyrimidine-2,4-diamine,
 N^4 -(2,2-Dimethylpropyl)-6-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)pyrimidine-2,4-diamine,
 N^4 -(2,2-Dimethylpropyl)-6-(3-pyrrolidin-1-ylazetidin-1-yl)pyrimidine-2,4-diamine,
 40 N^4 -(2,2-Dimethylpropyl)-6-[3-(isopropylamino)azetidin-1-yl]pyrimidine-2,4-diamine,
 N^4 -(*tert*-Butyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine,

- 6-[(3R)-3-(Methylamino)pyrrolidin-1-yl]-N⁴-(1-methylcyclopropyl)pyrimidine-2,4-diamine,
 N⁴-(*tert*-Butyl)-6-[(4aS*,7aS*)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine,
 N⁴-(2,2-Dimethylpropyl)-6-piperazin-1-ylpyrimidine-2,4-diamine,
 N⁴-(2,2-Dimethylpropyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine hydrochloride,
 5 N⁴-(2,2-Dimethylpropyl)-6-[(3aR*,7aS*)-octahydro-5H-pyrrolo[3,2-c]pyridin-5-yl]pyrimidine-2,4-diamine,
 6-Piperazin-1-yl-N⁴-propylpyrimidine-2,4-diamine,
 N⁴-(Cyclopropylmethyl)-6-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine,
 N⁴-(2,2-Dimethylpropyl)-6-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine,
 N⁴-(Cyclopropylmethyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine,
 10 N⁴-Isopropyl-6-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine,
 4-[3-(Methylamino)azetidin-1-yl]-6-(4-methylpiperidin-1-yl)pyrimidin-2-amine,
 N⁴-(Cyclopentylmethyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine,
 N⁴-Cyclobutyl-6-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine,
 6-[(3R)-3-(Methylamino)pyrrolidin-1-yl]-N⁴-propylpyrimidine-2,4-diamine, and,
 15 N⁴-Ethyl-6-(4-methyl-1,4-diazepan-1-yl)pyrimidine-2,4-diamine,
 or a pharmaceutically and/or veterinarily acceptable derivative thereof.

A further embodiment of the invention provides the following compounds:

- N⁴-(Cyclopropylmethyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine,
 20 N⁴-(Cyclopropylmethyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine tartrate,
 N⁴-(2,2-Dimethylpropyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine, and,
 N⁴-(2,2-Dimethylpropyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine hydrochloride,
 or a pharmaceutically and/or veterinarily acceptable derivative thereof.

- 25 By pharmaceutically and/or veterinarily acceptable derivative it is meant any pharmaceutically or
 veterinarily acceptable salt, solvate, ester or amide, or salt or solvate of such ester or amide, of the
 compounds of formula (I) or any other compound which upon administration to the recipient is capable of
 providing (directly or indirectly) a compound of formula (I) or an active metabolite or residue thereof.
 Preferably, pharmaceutically and/or veterinarily acceptable derivative means any pharmaceutically or
 30 veterinarily acceptable salt or solvate of the compounds of formula (I)

Pharmaceutically acceptable salts of the compounds of formula (I) include the acid addition and base
 salts thereof.

- 35 Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include the
 acetate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate,
 citrate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate,
 hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate,
 maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate,
 40 oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, saccharate,
 stearate, succinate, tartrate, tosylate and trifluoroacetate salts.

Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts.

Hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts.

For a review on suitable salts, see Handbook of Pharmaceutical Salts: Properties, Selection, and Use by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).

Pharmaceutically acceptable salts of the compounds of formula (I) may be prepared by one or more of three methods:

- (i) by reacting the compound of formula (I) with the desired acid or base;
- (ii) by removing an acid- or base-labile protecting group from a suitable precursor of the compound of formula (I) or by ring-opening a suitable cyclic precursor, for example, a lactone or lactam, using the desired acid or base; or
- (iii) by converting one salt of the compound of formula (I) to another by reaction with an appropriate acid or base or by means of a suitable ion exchange column.

All three reactions are typically carried out in solution. The resulting salt may precipitate out and be collected by filtration or may be recovered by evaporation of the solvent. The degree of ionisation in the resulting salt may vary from completely ionised to almost non-ionised.

The compounds of the invention may exist in both unsolvated and solvated forms. The term 'solvate' is used herein to describe a molecular complex comprising the compound of the invention and a stoichiometric amount of one or more pharmaceutically acceptable solvent molecules, for example, ethanol. The term 'hydrate' is employed when said solvent is water.

Included within the scope of the invention are complexes such as clathrates, drug-host inclusion complexes wherein, in contrast to the aforementioned solvates, the drug and host are present in stoichiometric or non-stoichiometric amounts. Also included are complexes of the drug containing two or more organic and/or inorganic components which may be in stoichiometric or non-stoichiometric amounts. The resulting complexes may be ionised, partially ionised, or non-ionised. For a review of such complexes, see J Pharm Sci, 64 (8), 1269-1288, by Halebian (August 1975).

Hereinafter all references to compounds of formula (I) include derivatives thereof and complexes of the compound or derivatives thereof.

The compounds of the invention include compounds of formula (I) as hereinbefore defined, including all polymorphs and crystal habits thereof, prodrugs and isomers thereof (including optical, geometric and tautomeric isomers) as hereinafter defined and isotopically-labeled compounds of formula (I).

As indicated, so-called 'pro-drugs' of the compounds of formula (I) are also within the scope of the invention. Thus certain derivatives of compounds of formula (I) which may have little or no pharmacological activity themselves can, when administered into or onto the body, be converted into compounds of formula (I) having the desired activity, for example, by hydrolytic cleavage. Such derivatives are referred to as 'prodrugs'. Further information on the use of prodrugs may be found in Pro-drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Series (T. Higuchi and W. Stella) and Bioreversible Carriers in Drug Design, Pergamon Press, 1987 (ed. E. B. Roche, American Pharmaceutical Association).

Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities present in the compounds of formula (I) with certain moieties known to those skilled in the art as 'pro-moieties' as described, for example, in Design of Prodrugs by H. Bundgaard (Elsevier, 1985).

Some examples of prodrugs in accordance with the invention include:

- (i) where the compound of formula (I) contains a carboxylic acid functionality (-COOH), an ester thereof, for example, a compound wherein the hydrogen of the carboxylic acid functionality of the compound of formula (I) is replaced by (C₁-C₈)alkyl;
- (ii) where the compound of formula (I) contains an alcohol functionality (-OH), an ether thereof, for example, a compound wherein the hydrogen of the alcohol functionality of the compound of formula (I) is replaced by (C₁-C₈)alkanoyloxymethyl; and
- (iii) where the compound of formula (I) contains a primary or secondary amino functionality (-NH₂ or -NHR where R is not H), an amide thereof, for example, a compound wherein, as the case may be, one or both hydrogens of the amino functionality of the compound of formula (I) is/are replaced by (C₁-C₁₀)alkanoyl.

Further examples of replacement groups in accordance with the foregoing examples and examples of other prodrug types may be found in the aforementioned references.

Moreover, certain compounds of formula (I) may themselves act as prodrugs of other compounds of formula (I).

Also included within the scope of the invention are metabolites of compounds of formula (I), that is, compounds formed *in vivo* upon administration of the drug. Some examples of metabolites in accordance with the invention include:

- (i) where the compound of formula (I) contains a methyl group, an hydroxymethyl derivative thereof (-CH₃ → -CH₂OH);
- (ii) where the compound of formula (I) contains an alkoxy group, an hydroxy derivative thereof (-OR → -OH);
- (iii) where the compound of formula (I) contains a tertiary amino group, a secondary amino derivative thereof (-NR^aR^b → -NHR^a or -NHR^b);

(iv) where the compound of formula (I) contains a secondary amino group, a primary derivative thereof ($-NHR^a \rightarrow -NH_2$);

(v) where the compound of formula (I) contains a phenyl moiety, a phenol derivative thereof ($-Ph \rightarrow -PhOH$); and

5 (vi) where the compound of formula (I) contains an amide group, a carboxylic acid derivative thereof ($-CONR^cR^d \rightarrow COOH$).

10 Compounds of formula (I) containing one or more asymmetric carbon atoms can exist as two or more stereoisomers. Where structural isomers are interconvertible via a low energy barrier, tautomeric isomerism ('tautomerism') can occur. This can take the form of proton tautomerism in compounds of formula (I) containing, for example, an imino, keto, or oxime group, or so-called valence tautomerism in compounds which contain an aromatic moiety. It follows that a single compound may exhibit more than one type of isomerism.

15 Included within the scope of the present invention are all stereoisomers, geometric isomers and tautomeric forms of the compounds of formula (I), including compounds exhibiting more than one type of isomerism, and mixtures of one or more thereof. Also included are acid addition or base salts wherein the counterion is optically active, for example, *d*-lactate, *l*-tartrate or *l*-lysine, or racemic, for example, *dl*-tartrate or *dl*-arginine.

20 Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC).

25 Alternatively, the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound of formula (I) contains an acidic or basic moiety, a base or acid such as 1-phenylethylamine or tartaric acid. The resulting diastereomeric mixture may be separated by chromatography and/or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to a skilled person.

30 Chiral compounds of the invention (and chiral precursors thereof) may be obtained in enantiomerically-enriched form using chromatography, typically HPLC, on an asymmetric resin.

35 Stereoisomeric conglomerates may be separated by conventional techniques known to those skilled in the art - see, for example, Stereochemistry of Organic Compounds by E. L. Eliel and S. H. Wilen (Wiley, New York, 1994).

40 The present invention includes all pharmaceutically acceptable isotopically-labelled compounds of formula (I) wherein one or more atoms are replaced by atoms having the same atomic number, but an

atomic mass or mass number different from the atomic mass or mass number which predominates in nature.

5 Examples of isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen, such as ^2H and ^3H , carbon, such as ^{11}C , ^{13}C and ^{14}C , chlorine, such as ^{36}Cl , fluorine, such as ^{18}F , iodine, such as ^{123}I and ^{125}I , nitrogen, such as ^{13}N and ^{15}N , oxygen, such as ^{15}O , ^{17}O and ^{18}O , phosphorus, such as ^{32}P , and sulphur, such as ^{35}S .

10 Certain isotopically labelled compounds of formula (I), for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, *i.e.* ^3H , and carbon-14, *i.e.* ^{14}C , are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.


15 Substitution with heavier isotopes such as deuterium, *i.e.* ^2H , may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased *in vivo* half-life or reduced dosage requirements, and hence may be preferred in some circumstances.

20 Substitution with positron emitting isotopes, such as ^{11}C , ^{18}F , ^{15}O and ^{13}N , can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.

Isotopically labelled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically labelled reagent in place of the non-labelled reagent previously employed.

25 Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, *e.g.* D_2O , d_6 -acetone, d_6 -DMSO.

Compounds of formula (I) may be prepared according to scheme 1 that follows.



wherein R^1 , R^2 , R^3 , R^4 , R^5 and R^8 are as defined above, and X and Y are leaving groups.

According to scheme 1, compounds of formula (I) may be prepared by the reaction of a compound of formula (II) with a suitable amine. Conveniently reaction is effected by using an excess of the amine or stoichiometric quantity of the amine in the presence of a base such as a tertiary amine base (e.g. triethylamine or N-ethyl-N-isopropylpropan-2-amine); optionally in the presence of a suitable solvent (e.g. dimethyl sulphoxide or 1-methylpyrrolidin-2-one); optionally in the presence of a catalyst (such as caesium fluoride); and at elevated temperature, such as 120°C to 150°C.

Compounds of formula (II) may be prepared by reaction of a compound of formula (III) with a suitable amine. Conveniently reaction is effected by using an excess of the amine or stoichiometric quantity of the amine in the presence of a base such as a tertiary amine base (e.g. triethylamine or N-ethyl-N-isopropylpropan-2-amine); in the presence of a suitable solvent (e.g. ethanol, 2-propanol or 1-methylpyrrolidin-2-one); and at ambient or elevated temperature, such as ambient temperature to 85°C.

According to scheme 1, the groups X and Y represent a halogen atom (e.g. chlorine) or an alternative leaving group such as a sulphonate ester (e.g. 4-methylphenyl sulphonate) or a sulphonyl group (e.g. methane sulphonyl or phenyl sulphonyl) or a sulphinyl group (e.g. methane sulphinyl).

It will be appreciated by those skilled in the art that the transformations described may be carried out in a manner that does not require the isolation or purification of the intermediate compound of formula (II) but that requires sequential addition of suitable amines, with or without additional base (e.g. triethylamine or N-ethyl-N-isopropylpropan-2-amine) or solvent, to a compound of formula (III) in the presence of a suitable solvent (e.g. 1-methylpyrrolidin-2-one or dimethyl sulphoxide) with or without heating the reaction

mixture between the addition of the two amines, and with or without the addition of a catalyst (such as caesium fluoride).

5 It will be further appreciated by those skilled in the art that it may be necessary or desirable to carry out the transformations described in the schemes in a different order from that described, or to modify one or more of the transformations, to provide the desired compound of formula (I).

10 It will be appreciated by those skilled in the art that, as illustrated in the schemes above, it may be necessary or desirable at any stage in the synthesis of compounds of formula (I) to protect one or more sensitive groups in the molecule so as to prevent undesirable side reactions. In particular, it may be necessary or desirable to protect amino groups. The protecting groups used in the preparation of compounds of formula (I) may be used in conventional manner. See, for example, those described in 'Protective Groups in Organic Synthesis' by Theodora W Green and Peter G M Wuts, third edition, (John Wiley and Sons, 1999), in particular chapter 7, pages 494-653 ("Protection for the Amino Group"),
15 incorporated herein by reference, which also describes methods for the removal of such groups.

Compounds of formula (III) are known in the literature or easily prepared by methods well known to those skilled in the art.

20 The compounds of the invention intended for pharmaceutical use may be administered as crystalline or amorphous products. They may be obtained, for example, as solid plugs, powders, or films by methods such as precipitation, crystallization, freeze drying, spray drying, or evaporative drying. Microwave or radio frequency drying may be used for this purpose.

25 They may be administered alone or in combination with one or more other compounds of the invention or in combination with one or more other drugs (or as any combination thereof). Generally, they will be administered as a formulation in association with one or more pharmaceutically acceptable excipients. The term 'excipient' is used herein to describe any ingredient other than the compound(s) of the invention. The choice of excipient will to a large extent depend on factors such as the particular mode of
30 administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.

Pharmaceutical compositions suitable for the delivery of compounds of the present invention and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in Remington's Pharmaceutical Sciences, 19th
35 Edition (Mack Publishing Company, 1995).

The compounds of the invention may be administered orally. Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed by which the compound enters the blood stream directly from the mouth.

Formulations suitable for oral administration include solid formulations such as tablets, capsules containing particulates, liquids, or powders, lozenges (including liquid-filled), chews, multi- and nano-particulates, gels, solid solution, liposome, films, ovules, sprays and liquid formulations.

- 5 Liquid formulations include suspensions, solutions, syrups and elixirs. Such formulations may be employed as fillers in soft or hard capsules and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.

10

The compounds of the invention may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Expert Opinion in Therapeutic Patents, 11 (6), 981-986, by Liang and Chen (2001).

- 15 For tablet dosage forms, depending on dose, the drug may make up from 1 weight % to 80 weight % of the dosage form, more typically from 5 weight % to 60 weight % of the dosage form. In addition to the drug, tablets generally contain a disintegrant. Examples of disintegrants include sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl cellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropyl
20 cellulose, starch, pregelatinised starch and sodium alginate. Generally, the disintegrant will comprise from 1 weight % to 25 weight %, preferably from 5 weight % to 20 weight % of the dosage form.

- Binders are generally used to impart cohesive qualities to a tablet formulation. Suitable binders include microcrystalline cellulose, gelatin, sugars, polyethylene glycol, natural and synthetic gums,
25 polyvinylpyrrolidone, pregelatinised starch, hydroxypropyl cellulose and hydroxypropyl methylcellulose. Tablets may also contain diluents, such as lactose (monohydrate, spray-dried monohydrate, anhydrous and the like), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and dibasic calcium phosphate dihydrate.

- 30 Tablets may also optionally comprise surface active agents, such as sodium lauryl sulfate and polysorbate 80, and glidants such as silicon dioxide and talc. When present, surface active agents may comprise from 0.2 weight % to 5 weight % of the tablet, and glidants may comprise from 0.2 weight % to 1 weight % of the tablet.

- 35 Tablets also generally contain lubricants such as magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, and mixtures of magnesium stearate with sodium lauryl sulphate. Lubricants generally comprise from 0.25 weight % to 10 weight %, preferably from 0.5 weight % to 3 weight % of the tablet.

- 40 Other possible ingredients include anti-oxidants, colorants, flavouring agents, preservatives and taste-masking agents.

Exemplary tablets contain up to about 80% drug, from about 10 weight % to about 90 weight % binder, from about 0 weight % to about 85 weight % diluent, from about 2 weight % to about 10 weight % disintegrant, and from about 0.25 weight % to about 10 weight % lubricant.

5

Tablet blends may be compressed directly or by roller to form tablets. Tablet blends or portions of blends may alternatively be wet-, dry-, or melt-granulated, melt congealed, or extruded before tableting. The final formulation may comprise one or more layers and may be coated or uncoated; it may even be encapsulated.

10

The formulation of tablets is discussed in Pharmaceutical Dosage Forms: Tablets, Vol. 1, by H. Lieberman and L. Lachman (Marcel Dekker, New York, 1980).

15

Consumable oral films for human or veterinary use are typically pliable water-soluble or water-swellaable thin film dosage forms which may be rapidly dissolving or mucoadhesive and typically comprise a compound of formula (I), a film-forming polymer, a binder, a solvent, a humectant, a plasticiser, a stabiliser or emulsifier, a viscosity-modifying agent and a solvent. Some components of the formulation may perform more than one function.

20

The compound of formula (I) may be water-soluble or insoluble. A water-soluble compound typically comprises from 1 weight % to 80 weight %, more typically from 20 weight % to 50 weight %, of the solutes. Less soluble compounds may comprise a greater proportion of the composition, typically up to 88 weight % of the solutes. Alternatively, the compound of formula (I) may be in the form of multiparticulate beads.

25

The film-forming polymer may be selected from natural polysaccharides, proteins, or synthetic hydrocolloids and is typically present in the range 0.01 to 99 weight %, more typically in the range 30 to 80 weight %.

30

Other possible ingredients include anti-oxidants, colorants, flavourings and flavour enhancers, preservatives, salivary stimulating agents, cooling agents, co-solvents (including oils), emollients, bulking agents, anti-foaming agents, surfactants and taste-masking agents.

35

Films in accordance with the invention are typically prepared by evaporative drying of thin aqueous films coated onto a peelable backing support or paper. This may be done in a drying oven or tunnel, typically a combined coater dryer, or by freeze-drying or vacuuming.

40

Solid formulations for oral administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.

Suitable modified release formulations for the purposes of the invention are described in US Patent No. 6,106,864. Details of other suitable release technologies such as high energy dispersions and osmotic and coated particles are to be found in Pharmaceutical Technology On-line, 25(2), 1-14, by Verma *et al* (2001). The use of chewing gum to achieve controlled release is described in WO 00/35298.

5

The compounds of the invention may also be administered directly into the blood stream, into muscle, or into an internal organ. Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous. Suitable devices for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.

10

Parenteral formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.

15

The preparation of parenteral formulations under sterile conditions, for example, by lyophilisation, may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.

The solubility of compounds of formula (I) used in the preparation of parenteral solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of solubility-enhancing agents.

20

Formulations for parenteral administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release. Thus compounds of the invention may be formulated as a solid, semi-solid, or thixotropic liquid for administration as an implanted depot providing modified release of the active compound. Examples of such formulations include drug-coated stents and poly(*dl*-lactic-co-glycolic)acid (PGLA) microspheres.

25

30

The compounds of the invention may also be administered topically to the skin or mucosa, that is, dermally or transdermally. Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibres, bandages and microemulsions. Liposomes may also be used. Typical carriers include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol. Penetration enhancers may be incorporated - see, for example, J Pharm Sci, 88 (10), 955-958, by Finnin and Morgan (October 1999).

35

Other means of topical administration include delivery by electroporation, iontophoresis, phonophoresis, sonophoresis and microneedle or needle-free (e.g. Powderject™, Bioject™, etc.) injection.

40

Formulations for topical administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.

- 5 The compounds of the invention can also be administered intranasally or by inhalation, typically in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with lactose, or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler or as an aerosol spray from a pressurised container, pump, spray, atomiser (preferably an atomiser using electrohydrodynamics to produce a fine mist), or nebuliser, with or without the use of a
- 10 suitable propellant, such as 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane. For intranasal use, the powder may comprise a bioadhesive agent, for example, chitosan or cyclodextrin.

- The pressurised container, pump, spray, atomizer, or nebuliser contains a solution or suspension of the compound(s) of the invention comprising, for example, ethanol, aqueous ethanol, or a suitable alternative
- 15 agent for dispersing, solubilising, or extending release of the active, a propellant(s) as solvent and an optional surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.

- Prior to use in a dry powder or suspension formulation, the drug product is micronised to a size suitable for delivery by inhalation (typically less than 5 microns). This may be achieved by any appropriate
- 20 comminuting method, such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenisation, or spray drying.

- Capsules (made, for example, from gelatin or hydroxypropyl-methylcellulose), blisters and cartridges for use in an inhaler or insufflator may be formulated to contain a powder mix of the compound of the
- 25 invention, a suitable powder base such as lactose or starch and a performance modifier such as *L*-leucine, mannitol, or magnesium stearate. The lactose may be anhydrous or in the form of the monohydrate, preferably the latter. Other suitable excipients include dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose and trehalose.

- 30 A suitable solution formulation for use in an atomiser using electrohydrodynamics to produce a fine mist may contain from 1µg to 20mg of the compound of the invention per actuation and the actuation volume may vary from 1µl to 100µl. A typical formulation may comprise a compound of formula (I), propylene glycol, sterile water, ethanol and sodium chloride. Alternative solvents which may be used instead of propylene glycol include glycerol and polyethylene glycol.

- 35 Suitable flavours, such as menthol and levomenthol, or sweeteners, such as saccharin or saccharin sodium, may be added to those formulations of the invention intended for inhaled/intranasal administration.

Formulations for inhaled/intranasal administration may be formulated to be immediate and/or modified release using, for example, PGLA. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.

- 5 In the case of dry powder inhalers and aerosols, the dosage unit is determined by means of a valve which delivers a metered amount or the drug product is packaged as discrete single dose units for use in the inhaler device. Units in accordance with the invention are typically arranged to administer a metered dose or "puff" containing from 1 μg to 4000 μg of the compound of formula (I). The overall daily dose will typically be in the range 1 μg to 20 mg which may be administered in a single dose or, more usually, as
10 divided doses throughout the day.

The compounds of the invention may be administered rectally or vaginally, for example, in the form of a suppository, pessary, or enema. Cocoa butter is a traditional suppository base, but various alternatives may be used as appropriate.

- 15 Formulations for rectal/vaginal administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.

- 20 The compounds of the invention may also be administered directly to the eye or ear, typically in the form of drops of a micronised suspension or solution in isotonic, pH-adjusted, sterile saline. Other formulations suitable for ocular and aural administration include ointments, biodegradable (e.g. absorbable gel sponges, collagen) and non-biodegradable (e.g. silicone) implants, wafers, lenses and particulate or vesicular systems, such as niosomes or liposomes. A polymer such as cross-linked polyacrylic acid,
25 polyvinylalcohol, hyaluronic acid, a cellulosic polymer, for example, hydroxypropylmethylcellulose, hydroxyethylcellulose, or methyl cellulose, or a heteropolysaccharide polymer, for example, gelatin gum, may be incorporated together with a preservative, such as benzalkonium chloride. Such formulations may also be delivered by iontophoresis.

- 30 Formulations for ocular/aural administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted, or programmed release.

- The compounds of the invention may be combined with soluble macromolecular entities, such as
35 cyclodextrin and suitable derivatives thereof or polyethylene glycol-containing polymers, in order to improve their solubility, dissolution rate, taste-masking, bioavailability and/or stability for use in any of the aforementioned modes of administration.

- Drug-cyclodextrin complexes, for example, are found to be generally useful for most dosage forms and
40 administration routes. Both inclusion and non-inclusion complexes may be used. As an alternative to direct complexation with the drug, the cyclodextrin may be used as an auxiliary additive, i.e. as a carrier,

diluent, or solubiliser. Most commonly used for these purposes are alpha-, beta- and gamma-cyclodextrins, examples of which may be found in International Patent Applications Nos. WO 91/11172, WO 94/02518 and WO 98/55148.

5 Inasmuch as it may be desirable to administer a combination of active compounds, for example, for the purpose of treating a particular disease or condition, it is within the scope of the present invention that two or more pharmaceutical compositions, at least one of which contains a compound in accordance with the invention, may conveniently be combined in the form of a kit suitable for coadministration of the compositions.

10

Thus the kit of the invention comprises two or more separate pharmaceutical compositions, at least one of which contains a compound of formula (I) in accordance with the invention, and means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet. An example of such a kit is the familiar blister pack used for the packaging of tablets, capsules and the like.

15

The kit of the invention is particularly suitable for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another. To assist compliance, the kit typically comprises directions for administration and may be provided with a so-called memory aid.

20

For administration to human patients, the total daily dose of the compounds of the invention is typically in the range 0.001 mg to 2000 mg depending, of course, on the mode of administration. For example, oral administration may require a total daily dose of from 0.1 mg to 2000 mg, while an intravenous dose may only require from 0.01 mg to 100 mg. The total daily dose may be administered in single or divided doses

25

and may, at the physician's discretion, fall outside of the typical range given herein.

These dosages are based on an average human subject having a weight of about 60 kg to 70 kg. The physician will readily be able to determine doses for subjects whose weight falls outside this range, such as infants and the elderly.

30

For the avoidance of doubt, references herein to "treatment" include references to curative, palliative and prophylactic treatment.

35

According to another embodiment of the present invention, the compounds of the invention can also be used as a combination with one or more additional therapeutic agents to be co-administered to a patient to obtain some particularly desired therapeutic end result. The second and more additional therapeutic agents may also be a compound of the formula (I) or a pharmaceutically and/or veterinarily acceptable derivative thereof, or one or more histamine H₄ receptor ligands known in the art. More typically, the second and more therapeutic agents will be selected from a different class of therapeutic agents.

40

As used herein, the terms "co-administration", "co-administered" and "in combination with", referring to the compounds of the invention and one or more other therapeutic agents, is intended to mean, and does refer to and include the following:

- 5 • simultaneous administration of such combination of compound(s) of formula (I) and therapeutic agent(s) to a patient in need of treatment, when such components are formulated together into a single dosage form which releases said components at substantially the same time to said patient,
- substantially simultaneous administration of such combination of compound(s) of formula (I) and therapeutic agent(s) to a patient in need of treatment, when such components are formulated apart from each other into separate dosage forms which are taken at substantially the same time by said patient, whereupon said components are released at substantially the same time to said patient,
- 10 • sequential administration of such combination compound(s) of formula (I) and therapeutic agent(s) to a patient in need of treatment, when such components are formulated apart from each other into separate dosage forms which are taken at consecutive times by said patient with a significant time interval between each administration, whereupon said components are released at substantially different times to said patient; and
- 15 • sequential administration of such combination of compound(s) of formula (I) and therapeutic agent(s) to a patient in need of treatment, when such components are formulated together into a single dosage form which releases said components in a controlled manner whereupon they are concurrently, consecutively, and/or overlappingly administered at the same and/or different times by said patient,
- 20

where each part may be administered by either the same or different route.

Suitable examples of other therapeutic agents which may be used in combination with the compound(s) of the invention or compositions thereof, include, but are by no means limited to :

- 25 • Histamine H₁ receptor antagonists, in particular loratidine, desloratidine, fexofenadine and cetirizine
- Histamine H₃ receptor antagonists
- Histamine H₂ receptor antagonists
- Leukotriene antagonists, including antagonists of LTB₄, LTC₄, LTD₄, and LTE₄; for example Montelukast
- 30 • Phosphodiesterase inhibitors, including PDE3 inhibitors, PDE4 inhibitors, PDE5 inhibitors, PDE7 inhibitors and inhibitors of two or more phosphodiesterases, such as dual PDE3/PDE4 inhibitors
- neurotransmitter re-uptake inhibitors, in particular fluoxetine, setraline, paroxetine, ziprasidone
- 5-Lipoxygenase (5-LO) inhibitors or 5-lipoxygenase activating protein (FLAP) antagonists
- α_1 - and α_2 -adrenoceptor agonist vasoconstrictor sympathomimetic agents for decongestant use
- 35 • Muscarinic M3 receptor antagonists or anticholinergic agents
- β_2 -adrenoceptor agonists
- Dual acting β_2 /M3 agents
- Xanthines, such as theophylline and aminophylline
- Non-steroidal anti-inflammatories, such as sodium cromoglycate and nedocromil sodium
- 40 • Ketotifen

- COX-1 inhibitors (NSAIDs) and COX-2 selective inhibitors
- Oral or inhaled Glucocorticosteroids
- Monoclonal antibodies active against endogenous inflammatory entities
- Anti-tumor necrosis factor (anti-TNF- α) agents
- 5 • Adhesion molecule inhibitors including VLA-4 antagonists
- Kinin-B₁ - and B₂ -receptor antagonists
- Immunosuppressive agents
- Inhibitors of matrix metalloproteases (MMPs)
- Tachykinin NK₁, NK₂ and NK₃ receptor antagonists
- 10 • Elastase inhibitors
- Adenosine A2a receptor agonists
- Inhibitors of urokinase
- Compounds that act on dopamine receptors, e.g. D2 agonists
- Modulators of the NF κ b pathway, e.g. IKK inhibitors
- 15 • Agents that can be classed as mucolytics or anti-tussive
- Antibiotics
- Modulators of cytokine signaling pathways, such as p38 MAP kinase inhibitors, syk tyrosine kinase inhibitors or JAK kinase inhibitors
- Modulators of the prostaglandin pathways, including inhibitors of H-PDGS and antagonists of DP-1 and CRTH2
- 20 • Antagonists of chemokine receptors CXCR1 and CXCR2
- Antagonists of chemokine receptors CCR3, CCR4 and CCR5
- Inhibitors of cytosolic and soluble phospholipase A₂ (cPLA₂ and sPLA₂)
- Prostaglandin D2 receptor antagonists (DP1 and CRTH2)
- 25 • Inhibitors of Prostaglandin D synthase (PGDS)
- Inhibitors of phosphoinositide-3-kinase,
- HDAC inhibitors,
- p38 inhibitors and/or
- CXCR2 antagonists.

30

According to the present invention, combination of the compounds of formula (I) with:

- Histamine H₁ receptor antagonists, in particular loratidine, desloratidine, fexofenadine and cetirizine,
- Histamine H₃ receptor antagonists,
- Histamine H₂ receptor antagonists,
- 35 • Leukotriene antagonists, including antagonists of LTB₄, LTC₄, LTD₄, and LTE₄, for example Montelukast, and/or,
- Phosphodiesterase PDE4 inhibitors

form a further embodiment of the invention.

The compounds of formula (I) have the ability to interact with the H₄ receptor and thereby have a wide range of therapeutic applications, as described further below, because of the essential role, which the H₄ receptor plays in the physiology of all mammals. According to this invention H₄ ligands are meant to include H₄ receptor antagonists, agonists and inverse agonists. For the preferred indications to be treated according to the invention, H₄ antagonists are believed to be most suitable.

Therefore, a further aspect of the present invention relates to the compounds of formula (I) or pharmaceutically acceptable salts, derived forms or compositions thereof, for use as medicaments, more particularly in the treatment of diseases, disorders, and conditions in which the H₄ receptor is involved. More specifically, the present invention also concerns the compounds of the invention for use in the treatment of diseases, disorders, and conditions selected from the group consisting of:

- inflammatory diseases;
- respiratory diseases (e.g. adult respiratory distress syndrome, acute respiratory distress syndrome, bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, asthma, emphysema, rhinitis, chronic sinusitis), allergy, allergy-induced airway responses, allergic rhinitis, viral rhinitis, non-allergic rhinitis, perennial and seasonal rhinitis, nasal congestion, allergic congestion;
- female and male sexual dysfunction;
- skin diseases such as dermatitis and psoriasis;
- cardiac dysfunctions such as myocardial ischaemia and arrhythmia;
- diseases of the gastrointestinal tract such as inflammatory bowel disease, Crohn's disease and colitis ulcerosa;
- cancer;
- rheumatoid arthritis;
- hypotension;
- inflammatory pain and
- overactive bladder conditions.

The compounds of formula (I) according to the present invention are particularly suitable for the treatment of asthma, allergy, allergy-induced airway responses, allergic rhinitis, viral rhinitis, non-allergic rhinitis, perennial and seasonal rhinitis, nasal congestion and allergic congestion.

A still further aspect of the present invention also relates to the use of the compounds of the invention for the manufacture of a drug being a H₄ ligand. In particular, the present invention concerns the use of the compounds of formula (I), or pharmaceutically and/or veterinarily acceptable derivatives thereof, for the manufacture of a drug for the treatment of H₄ mediated diseases and/or conditions, in particular the diseases and/or conditions listed above.

As a consequence, the present invention provides a particularly interesting method to treat a mammal, including a human being, with an effective amount of a compound of formula (I), or a pharmaceutically

and/or veterinarily acceptable derivative thereof. More precisely, the present invention provides a particularly interesting method for the treatment of a H_4 mediated diseases and/or conditions in a mammal, including a human being, in particular the diseases and/or conditions listed above, comprising administering to said mammal an effective amount of a compound of the invention.

5

The compounds of the invention may have the advantage that they are more potent, have a longer duration of action, have a broader range of activity, are more stable, are easier and/or safer to prepare, have fewer side effects or are more selective, or have other more useful properties than the compounds of the prior art.

10 The following examples illustrate the preparation of compounds of formula (I) according to the present invention


1H Nuclear magnetic resonance (NMR) spectra were in all cases consistent with the proposed structures. Characteristic chemical shifts (δ) are given in parts-per-million (ppm) downfield from tetramethylsilane using conventional abbreviations for designation of major peaks: e.g. s (singlet), d (doublet), t (triplet), q (quartet) m (multiplet) and br (broad). The mass spectra (m/z) were recorded using either electrospray ionisation (ESI) or atmospheric pressure chemical ionisation (APCI). Purification by SCX indicates use of strong cation exchange resin.

20 In the examples section, the following abbreviations are used:

DCM	dichloromethane
DIPEA	N-ethyl-N-isopropylpropan-2-amine
DMSO	dimethyl sulphoxide
IPA	2-propanol
NMP	1-methylpyrrolidin-2-one
SCX	strong cation exchange
TEA	triethylamine
THF	tetrahydrofuran
TLC	thin-layer chromatography

Examples

25 **Preparation 1: *tert*-Butyl [1-(6-chloro-pyrimidin-4-yl)-azetidin-3-yl]-methyl-carbamate**



Azetidin-3-yl-methyl-carbamic acid *tert*-butyl ester (1.97 g, 11 mmol) in IPA (5 mL) was added dropwise to a stirred solution of 4,6-dichloropyrimidine (1.49 g, 10 mmol) in IPA (20 mL) followed by dropwise addition of TEA (2.11 mL, 15.1 mmol) at ambient temperature under N_2 . The resulting milky yellow solution was


heated to 80 °C and maintained at 80 °C for 2 hours. The solution was allowed to cool and evaporated to dryness to give a yellow oil. The crude material was partitioned between DCM (70 mL) and water (30 mL). The aqueous extract was re-extracted with DCM (70 mL). The combined organic extract was washed with saturated aqueous sodium bicarbonate (30 mL), dried (MgSO₄), filtered and evaporated to give a golden coloured oil. The crude oil was purified by flash column chromatography on silica gel eluting with DCM : MeOH (99 : 1 changing to 96 : 4 by volume) to yield the title compound as a solid (1.93 g, 64%).

¹H NMR (400MHz, CD₃OD): δ 8.25 (1H, d), 6.47 (1H, s), 4.9 (1H, br s), 4.31 (2H, t), 4.21 (2H, m), 2.94 (3H, s), 1.45 (9H, s) ppm.





MS (ESI) m/z 299 [M+H]⁺

Preparations 2 to 11


The following compounds of the general formula shown below were prepared by a method similar to that described for preparation 1 using the appropriate starting material and 4,6-dichloropyrimidine. The reactions were monitored by TLC analysis and were heated to reflux for 3 to 18 hours.



No.	NRR'	Name	Yield	LRMS m/z
2		(3R)-1-(6-Chloropyrimidin-4-yl)-N,N-dimethylpyrrolidin-3-amine	66%	227
3		(3S)-1-(6-Chloropyrimidin-4-yl)-N,N-dimethylpyrrolidin-3-amine	81%	227
4		(3aR*,6aS*)-2-(6-Chloropyrimidin-4-yl)-5-methyloctahydropyrrolo[3,4-c]pyrrole	77%	239
5		1-(6-Chloropyrimidin-4-yl)-N,N-dimethylazetidin-3-amine	55%	213
6		4-Chloro-6-(4-methylpiperazin-1-yl)pyrimidine	77%	213
7		(1S,4S)-2-(6-Chloropyrimidin-4-yl)-5-methyl-2,5-diazabicyclo[2.2.1]heptane	97%	225

8		N-[(3R)-1-Benzylpyrrolidin-3-yl]-6-chloropyrimidin-4-amine	6-	64%	289
9		N-[(3S)-1-Benzylpyrrolidin-3-yl]-6-chloropyrimidin-4-amine		49%	289
10		<i>tert</i> -Butyl [(3R)-1-(6-chloropyrimidin-4-yl)pyrrolidin-3-yl]methylcarbamate		86%	313
11		<i>tert</i> -Butyl [(3S)-1-(6-chloropyrimidin-4-yl)pyrrolidin-3-yl]methylcarbamate		95%	313

Preparation 12: *tert*-Butyl [1-(2-amino-6-chloro-pyrimidin-4-yl)-azetidin-3-yl]-methyl-carbamate




2-Amino-4,6-dichloropyrimidine (26.2 g, 160 mmol) was added portionwise to a stirred solution of azetidin-3-yl-methyl-carbamic acid *tert*-butyl ester HCl salt (37.4 g, 168 mmol) in absolute EtOH (400 mL) followed by TEA (55.6 mL, 400 mmol) dropwise at ambient temperature. The resulting suspension was warmed to reflux (initially a clear solution was observed on warming) which resulted in the gradual formation of a precipitate. The mixture was refluxed for a total of 2 hours. The mixture was allowed to cool and diluted with water (200 mL) dropwise over 30 min and stirring continued for 45 min. The resulting solid was filtered, washed with water (150 mL) and dried under suction to yield the title compound as a white solid (42.74 g, 85%).

¹H NMR (400MHz, CDCl₃): δ 5.66 (1H, s), 5.02 (1H, br s), 4.86 (2H, br s), 4.20 (2H, t), 4.04 (2H, m), 2.91 (3H, s), 1.47 (9H, s) ppm.

MS (APCI) m/z 314 [M+H]⁺

Preparation 13: 4-Chloro-6-[(3aR,6aS)-5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]pyrimidin-2-amine




2-Amino-4,6-dichloropyrimidine (1.64 g, 10 mmol) was added portionwise to a stirred solution (3aR,6aS)-2-methyloctahydropyrrolo[3,4-c]pyrrole (1.6 g, 12.5 mmol) in absolute EtOH (10 mL) followed by TEA (1.8 mL, 12.5 mmol) dropwise at ambient temperature. The resulting suspension was warmed to reflux (initially a clear solution was observed on warming) and resulted in the gradual formation of a tan coloured precipitate. The mixture was refluxed for a total of 3 hours. The mixture was allowed to cool, EtOH (30 mL) was added to the mixture and heated to give a solution and was left to cool to ambient temperature. The resulting solid was collected by filtration, washed with cold EtOH (50 mL) and dried under suction to yield the title compound as a solid (2.07 g, 82%).

¹H NMR (400MHz, CD₃OD): δ 5.88 (1H, s), 3.62 (2H, m), 3.41 (2H, m), 3.0 (2H, m), 2.78 (2H, m), 2.47 (2H, dd), 2.33 (3H, s) ppm.

MS (APCI) m/z 254, 256 [M+H]⁺

Preparation 14: *tert*-Butyl (4aR*,7aR*)-6-(2-amino-6-chloropyrimidin-4-yl)octahydro-1H-pyrrolo[3,4-b]pyridine-1-carboxylate




To a solution of racemic *tert*-butyl (4aR*,7aR*)-octahydro-1H-pyrrolo[3,4-b]pyridine-1-carboxylate (460 mg, 2.03 mmol) in EtOH (1 mL) containing DIPEA (590 µL, 3.39 mmol) was added a solution of 2-amino-4,6-dichloropyrimidine (277 mg, 169 mmol) in EtOH (9 mL) with stirring and the solution was heated to reflux for 24 hours. The solution was cooled and diluted with water (10 mL) and the resulting solid was collected by filtration, washed with water (20 mL) and dried *in vacuo* at 60 °C to yield the title compound as a white solid (558 mg, 93%).





¹H NMR (400MHz, CD₃OD): δ 5.85 (1H, s), 4.7 (1H, m), 3.98 (1H, m), 3.8 - 3.55 (1H, m), 3.47 (1H, m), 3.45 - 3.15 (1H, m), 2.85 (1H, m), 2.25 (1H, m), 1.85 - 1.65 (2H, m), 1.5 - 1.15 (12H, m)

MS (APCI) m/z 354, 356 [M+H]⁺


Preparations 15 to 19

The following compounds of the general formula shown below were prepared by a method similar to that described for preparation 1 using the appropriate amine and 2-amino-4,6-dichloropyrimidine. The reactions were monitored by TLC analysis and were heated to reflux for 3 to 18 hours.



No.	NRR'	Name	Yield	LRMS m/z
15		<i>tert</i> -Butyl [(3R)-1-(2-amino-6-chloropyrimidin-4-yl)pyrrolidin-3-yl]methylcarbamate	100%	328
16		6-Chloro-N'-(3,3-dimethylbutyl)pyrimidine-2,4-diamine	99%	229
17		6-Chloro-N'-ethylpyrimidine-2,4-diamine	73%	173
18		6-Chloro-N'-(3-fluorobenzyl)pyrimidine-2,4-diamine	75%	253
19		6-Chloro-N'-(2,2-dimethylpropyl)pyrimidine-2,4-diamine	66%	213

Alternative method for preparation 15 : *tert*-Butyl [(3R)-1-(2-amino-6-chloropyrimidin-4-yl)pyrrolidin-3-yl]methylcarbamate



5

A suspension of 2-amino-4,6-dichloropyrimidine (3.62g, 22.1mmol) and the amine of preparation 47 (5.40g, 27.0mmol) in ethanol (45ml) was treated with TEA (4.62ml, 33.1mmol) and the resulting mixture heated at 80°C for 1 hour. The reaction was cooled to room temperature and partitioned between ethyl acetate and water. The organic phase was separated and the aqueous extracted with further ethyl acetate. The combined organic extracts were dried (magnesium sulphate) and the solvent removed in vacuo to give an orange oil. Trituration with di-isopropyl ether gave a pale yellow solid which was filtered and dried in vacuo to give the title compound (7.0g, 87%).


10

¹H NMR (400MHz, DMSO_{d6}): δ 5.77 (1H, s), 4.60 (1H, br m), 3.27 (4H, br m), 2.70 (3H, s), 2.02 (2H, br m), 1.39 (9H, s) ppm.

15

MS (ESI) m/z 327 [M+H]⁺


Preparation 20: N-[(3S)-1-Benzylpyrrolidin-3-yl]-N'-(3,3-dimethylbutyl)pyrimidine-4,6-diamine



A solution of the title compound of preparation 9 (2.7 g, 9.4 mmol), 3,3-dimethylbutan-1-amine (6.3 mL, 46 mmol) and DIPEA (1.63 mL, 9.4 mmol) in NMP (100 mL) was heated to 150 °C in a sealed vessel for 24 hours. The reaction mixture was diluted with water (500 mL) and extracted with ethyl acetate (3 x 250 mL). The combined organic layers were washed with water (2 x 400 mL) followed by saturated aqueous sodium chloride (500 mL), dried (MgSO₄) and concentrated *in vacuo*. The residue was triturated with diethyl ether and the resulting solid collected by filtration to yield the title compound as a white powder (2.15 g, 65%).

MS (APCI) *m/z* 354 [M+H]⁺

10 **Preparation 21: *N*-[1-(3*R*)-1-Benzylpyrrolidin-3-yl]-*N'*-(3,3-dimethylbutyl)pyrimidine-4,6-diamine**




The title compound was prepared by a method similar to that described for preparation 20, using the title compound of preparation 8, in 48% yield.

MS (APCI) *m/z* 354 [M+H]⁺

15

Preparation 22: *tert*-Butyl {1-[6-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-azetidin-3-yl}-methyl-carbamate




To a 5 mL reacti-vialTM containing the title compound of preparation 1 (100 mg, 0.33 mmol) and cyclopropylmethylamine (50 mg, 0.68 mmol) in DMSO (3 mL) was added TEA (94 μL, 0.68 mmol) and the solution was heated at 140 °C for 18 hours. The reaction was allowed to cool to ambient temperature, loaded onto a 5g SCX column, eluted with MeOH (100 mL) followed by 2M ammonia in MeOH (100 mL). Fractions containing product (as judged by TLC) were combined and evaporate to give a crude orange oil. The crude product was purified by flash column chromatography on silica gel eluting with DCM :

25 MeOH (99 : 1 changing to 96 : 4 by volume) to yield the title compound as a colourless oil (75 mg, 67%).

¹H NMR (400MHz, CDCl₃): δ 8.13 (1H, s), 5.08 (1H, s), 4.79 (1H, br s), 4.20 (2H, t), 4.01 (2H, m), 3.04 (2H, t), 2.93 (3H, s), 1.46 (9H, s), 1.05 (1H, m), 0.55 (2H, m), 0.24 (2H, m) ppm.

MS (APCI) *m/z* 334 [M+H]⁺

30 **Preparation 23: *tert*-Butyl {1-[6-(3-fluoro-benzylamino)-pyrimidin-4-yl]-azetidin-3-yl}-methyl-carbamate**




To a 5ml reacti-vialTM containing the title compound of preparation 1 (100 mg, 0.33 mmol) and 3-fluorobenzylamine (76 μ L, 0.68 mmol) in DMSO (3 mL) was added TEA (9 μ L, 0.68 mmol) and the solution was heated at 140 °C for 18 hours. The reaction was allowed to cool to ambient temperature and concentrated *in vacuo* to obtain crude product as a viscous orange oil. The crude product was purified by flash column chromatography on silica gel eluting with DCM : MeOH (99 : 1 changing to 97 : 3 by volume) to yield the title compound as a light beige coloured solid (49 mg, 38%).

¹H NMR (400MHz, CDCl₃): δ 8.18 (1H, s), 7.30 (1H, m), 7.09 (1H, m), 7.02 (1H, d), 6.97 (1H, m), 5.09 (1H, s), 5.0 (1H, br d), 4.46 (2H, d), 4.17 (2H, t), 3.98 (2H, m), 2.92 (3H, s), 1.47 (9H, s) ppm.

MS (APCI) m/z 388 [M+H]⁺

Preparation 24: *tert*-Butyl (4aR*,7aR*)-6-{2-amino-6-[(3,3-dimethylbutyl)amino]pyrimidin-4-yl}octahydro-1H-pyrrolo[3,4-b]pyridine-1-carboxylate




To a solution of the title compound of preparation 14 (60 mg, 0.17 mmol) in DMSO (150 μ L) was added 3,3-dimethylbutan-1-amine (229 μ L, 1.7 mmol) and the reaction mixture was heated to 120 °C in a sealed vessel for 48 hours. The reaction mixture was diluted with water (4 mL) and extracted with ethyl acetate (4 mL). The organic extract was dried (MgSO₄) and concentrated *in vacuo*. The residue was dissolved in MeOH (0.5 mL) and purified using a phenomenex HPLC C-18 column eluting with acetonitrile:water (5 : 95 changing to 95 : 5 by volume containing 0.1% TFA by volume) to yield the title compound as a gum (45 mg, 63%).

¹H NMR (400MHz, CDCl₃): δ 8.41 – 8.33 (1H, m), 7.6 – 7.3 (1H, m), 6.15 (1H, br s), 4.92 – 4.69 (1H, m), 4.65 (1H, s), 4.05 (1H, d), 3.89 – 3.19 (5H, m), 3.17 – 3.09 (2H, m), 2.77 (1H, t), 2.39 – 2.19 (1H, m), 1.88 – 1.65 (2H, m), 1.62 – 1.51 (2H, m), 1.49 (9H, s), 1.44 – 1.17 (1H, m) 0.97 (9H, s) ppm.

MS (ESI) m/z 419 [M+H]⁺

Preparation 25: *tert*-Butyl (1-{2-amino-6-[(2,2-dimethylpropyl)amino]pyrimidin-4-yl}azetidin-3-yl)methyl-carbamate




To a solution of the title compound of preparation 12 (40 mg, 0.13 mmol) in DMSO (150 μ L) was added isopropylamine (150 μ L, 1.7 mmol) and the resulting mixture was heated to 120 °C in a sealed vessel for 48 hours. The reaction mixture was concentrated *in vacuo* to give a brown gum. The residual gum was purified by flash column chromatography on silica gel eluting with DCM : MeOH : 0.880 ammonia (990 : 10 : 1 changing to 190 : 10 : 1 by volume) to yield the title compound as a gum (20 mg, 42%).

¹H NMR (400MHz, CD₃OD): δ 4.83 (1H, s), 4.13 (2H, t), 3.97 (2H, dd), 3.01 (2H, s), 2.93 (3H, s), 1.46 (9H, s), 0.94 (9H, s) ppm.

MS (ESI) m/z 365 $[M+H]^+$

Preparation 26: *tert*-Butyl [1-(2-amino-6-isopropylamino-pyrimidin-4-yl)-azetidin-3-yl]-methyl-carbamate



5


To a solution of the title compound of preparation 12 (40 mg, 0.13 mmol) in DMSO (150 μ L) was added isopropylamine (150 μ L, 1.7 mmol) and the resulting mixture was heated to 120 °C in a sealed vessel for 48 hours. The reaction mixture was concentrated *in vacuo* to give a brown gum. The residual gum was purified by flash column chromatography on silica gel eluting with DCM : MeOH : 0.880 ammonia (990 :

10 : 1 changing to 190 : 10 : 1 by volume) to yield the title compound as a gum (22 mg, 50%).

^1H NMR (400MHz, CDCl_3): δ 4.95 (1H, br s), 4.67 (1H, s), 4.48 (2H, br s), 4.33 (1H, br d), 4.16 (2H, br t), 3.95 (2H, dd), 3.72 (1H, m), 2.92 (3H, s), 1.46 (9H, s), 1.19 (6H, d) ppm.

MS (APCI) m/z 337 $[M+H]^+$

15 **Preparation 27: *tert*-Butyl [1-(2-amino-6-(3,3,3-trifluoro-propylamino)-pyrimidin-4-yl)-azetidin-3-yl]-methyl-carbamate**




To a solution of the title compound of preparation 12 (30 mg, 0.1 mmol) in EtOH (200 μ L) was added 3,3,3 trifluoropropylamine hydrochloride (48 mg, 0.3 mmol) followed by TEA (100 μ L, 0.7 mmol) and the resulting mixture was heated under microwave irradiation to 130 °C in a sealed vessel for 90 min. The reaction mixture was concentrated *in vacuo* to give a brown gum. The residual gum was purified by flash column chromatography eluting with DCM : MeOH : 880 ammonia (99 : 1 : 0.1 changing to 95 : 5 : 0.5, by volume) to yield the title compound as a gum (15 mg, 38%).

20 ^1H NMR (400MHz, CD_3COCD_3): δ 5.71 (1H, br t), 5.13 (2H, br s), 4.87 (1H, br s), 4.84 (1H, s), 4.04 (2H, t), 3.88 (2H, dd), 3.54 (2H, q), 2.91 (3H, s), 2.52 (2H, m), 1.44 (9H, s) ppm.

MS (APCI) m/z 391 $[M+H]^+$

Preparation 28: *tert*-Butyl [1-(2-amino-6-(cyclopropylmethyl-amino)-pyrimidin-4-yl)-azetidin-3-yl]-methyl-carbamate




30

The title compound was prepared by a method similar to that described for preparation 26, using the title compound of preparation 12 and cyclopropylmethylamine, in 48% yield.

¹H NMR (400MHz, CD₃COCD₃): δ 5.51 (1H, m), 5.08 (2H, br s), 4.87 (1H, br s), 4.79 (1H, s), 4.03 (2H, t), 3.87 (2H, dd), 3.08 (2H, t), 2.90 (3H, s), 1.43 (9H, s), 1.02 (1H, m), 0.42 (2H, m), 0.19 (2H, m) ppm.

5 MS (APCI) m/z 349 [M+H]⁺

Preparation 29: tert-Butyl {1-[2-amino-6-(3,3-dimethyl-butylamino)-pyrimidin-4-yl]-azetidin-3-yl}-methyl-carbamate




10

The title compound was prepared by a method similar to that described for preparation 26, using the title compound of preparation 12 and 3,3-dimethylbutan-1-amine, in 58% yield.

¹H NMR (400MHz, CDCl₃): δ 5.0 (1H, br s), 4.67 (1H, s), 4.52 (2H, br s), 4.36 (1H br t), 4.16 (2H, t), 3.96 (2H, m), 3.13 (2H, m), 2.92 (3H, s), 1.50 – 1.45 (11H, m), 0.95 (9H, s) ppm.

15 MS (APCI) m/z 379 [M+H]⁺

Preparation 30: tert-Butyl {1-[2-amino-6-(3-fluoro-benzylamino)-pyrimidin-4-yl]-azetidin-3-yl}-methyl-carbamate



20 The title compound was prepared by a method similar to that described for preparation 26, using the title compound of preparation 12 and 3-fluorobenzylamine using 1,2-diethoxy-ethane as reaction solvent, in 53% yield.


¹H NMR (400MHz, CDCl₃): δ 7.28 (1H, m), 7.08 (1H, d), 7.01 (1H, br d), 6.95 (1H, br t), 5.15 (1H, br t), 5.00 (1H, br s), 4.80 (2H, br s), 4.64 (1H, s), 4.41 (2H, br d), 4.13 (2H, t), 3.96 (2H, dd), 2.90 (3H, s), 1.45 (9H, s) ppm.

25

MS (ESI) m/z 403 [M+H]⁺

Preparation 31: tert-Butyl {1-[2-amino-6-(3-methoxy-benzylamino)-pyrimidin-4-yl]-azetidin-3-yl}-methyl-carbamate


37



The title compound was prepared by a method similar to that described for preparation 26, using the title compound of preparation 12 and 3-methoxy-benzylamine, in 17% yield.

^1H NMR (400MHz, CD_3COCD_3): δ 7.20 (1H, t), 6.93 – 6.89 (2H, m), 6.78 (1H, dd), 5.96 (1H, br t), 5.12 (2H, br s), 5.00 – 4.70 (2H, m), 4.46 (2H, d), 4.01 (2H, t), 3.86 (2H, m), 3.76 (3H, s), 2.90 (3H, s), 1.44 (9H, s) ppm.

Preparation 32: *tert*-Butyl {1-[2-amino-6-(cyclobutylmethyl-amino)-pyrimidin-4-yl]-azetidin-3-yl}-methyl-carbamate




To a solution of the title compound of preparation 1 (30 mg, 0.10 mmol) in DMSO (150 μL) was added cyclobutylmethylamine hydrogen chloride (127 mg, 1 mmol) followed by DIPEA (300 μL , 1.76 mmol) and the resulting mixture was heated to 120 $^\circ\text{C}$ in a sealed vessel for 48 hours. The reaction mixture was concentrated *in vacuo* to give a gum. The residual gum was purified by flash column chromatography on silica gel eluting with DCM : MeOH : 0.880 ammonia (990 : 10 : 1 changing to 190 : 10 : 1 by volume) to yield the title compound as a gum (12 mg, 33%).

^1H NMR (400MHz, CD_3COCD_3): δ 5.52 (1H, m), 5.13 (2H, br s), 4.87 (1H, br s), 4.79 (1H, s), 4.05 (2H, t), 3.86 (2H, dd), 3.25 (2H, t), 2.91 (3H, s), 2.56 (1H, m), 2.05 – 1.97 (H, m), 1.89 – 1.80 (2H, m), 1.77 – 1.69 (2H, m), 1.44 (9H, s) ppm.

MS (ESI) m/z 363 $[\text{M}+\text{H}]^+$

Preparation 33: *tert*-Butyl {1-[2-amino-6-(cyclopentylmethyl-amino)-pyrimidin-4-yl]-azetidin-3-yl}-methyl-carbamate




The title compound was prepared by a method similar to that described for preparation 26, using the title compound of preparation 12 and cyclopentylmethylamine hydrogen chloride, in 16% yield.

^1H NMR (400MHz, CD_3OD): δ 4.79 (1H, s), 4.15 (2H, t), 4.00 (2H, dd), 3.10 (2H, d), 2.93 (3H, s), 2.14 (1H, m), 1.83 – 1.75 (2H, m), 1.69 – 1.53 (4H, m), 1.46 (9H, s), 1.30 – 1.22 (2H, m) ppm.

MS (APCI) m/z 377 [M+H]⁺**Preparations 34 to 42**


The following compounds of the general formula shown below were prepared by a method similar to that described for preparation 1 using the appropriate amine and 2-amino-4,6-dichloropyrimidine. Reactions were monitored by TLC analysis.



No.	NRR'	Name	LRMS m/z
34		<i>tert</i> -Butyl 4-(2-amino-6-chloropyrimidin-4-yl)-1,4-diazepane-1-carboxylate	328
35		6-Chloro-N ⁴ -(2-methylcyclopropyl)pyrimidine-2,4-diamine	199
36		4-Chloro-6-(4-methyl-1,4-diazepan-1-yl)pyrimidin-2-amine	242
37		6-Chloro-N ⁴ -(cyclopropylmethyl)pyrimidine-2,4-diamine	254
38		<i>tert</i> -Butyl (3aR*,7aS*)-5-(2-amino-6-chloropyrimidin-4-yl)octahydro-1H-pyrrolo[3,2-c]pyridine-1-carboxylate	354
39		N ⁴ -Bicyclo[1.1.1]pent-1-yl-6-chloropyrimidine-2,4-diamine	211
40		<i>tert</i> -Butyl [1-(2-amino-6-chloropyrimidin-4-yl)piperidin-4-yl]carbamate	328
41		<i>tert</i> -Butyl [1-(2-amino-6-chloropyrimidin-4-yl)-3-methylazetidin-3-yl]methylcarbamate	328
42		4-Chloro-6-(hexahydropyrrolo[12-a]pyrazin-2(1H)-yl)pyrimidin-2-amine	254

Preparation 43: N⁴-(*tert*-Butyl)-6-chloropyrimidine-2,4-diamine

39




A solution of 2-amino-4,6-dichloropyrimidine (400mg, 2.44mmol) and *t*-butylamine (2.6ml, 25.0mmol) in NMP (1ml) was heated in a microwave at 150°C for 60 minutes. The reaction mixture was partitioned between water (10ml) and ethyl acetate (10ml), the organic phase separated, dried and reduced in vacuo.

- 5 Purification by flash column chromatography on silica gel eluting with ethyl acetate:pentane (30:70 changing to 80:20 by volume) to yield the title compound as a colourless solid (494mg, 100%).

¹H NMR (400MHz, CDCl₃): δ 5.80 (1H, s), 4.78 (2H, bs), 1.42 (9H, s) ppm.

MS (ESI) *m/z* 201 [M+H]⁺

10 **Preparation 44: 6-Chloro-N⁴-(1-methylcyclopropyl)pyrimidine-2,4-diamine**




2-amino-4,6-dichloropyrimidine (508mg, 3.1mmol) was added to a suspension of 1-methylcyclopropylamine hydrochloride (1.0g, 9.3mmol) and sodium methoxide (502mg, 9.30mmol) in NMP (3ml). The resulting mixture was heated at 90°C for 16 hours and then cooled to room temperature.

- 15 The reaction mixture was diluted with water (20ml) and the resulting precipitate filtered off, washed with further water (20ml) and dried in vacuo to give the title compound as a colourless solid (280mg, 15%).

¹H NMR (400MHz, CDCl₃): δ 6.71 (1H, s), 1.37 (3H, s), 0.83-0.79 (2H, m), 0.72-0.65 (2H, m) ppm.

MS (ESI) *m/z* 199 [M+H]⁺

20 **Preparation 45 : Benzyl (3R)-3-[(*tert*-butoxycarbonyl)amino]pyrrolidine-1-carboxylate**




A solution of *tert*-Butyl (3S)-pyrrolidin-3-ylcarbamate (10.0g, 53.7mmol) in DCM (40ml) was treated with TEA (14.9ml, 107mmol) and cooled to 0°C. Benzyl chloroformate (7.6ml, 53.7mmol) was added dropwise and the resulting suspension was allowed to warm gradually to room temperature over a period of 18 hours. The reaction mixture was diluted with water (100ml) and the organic phase separated. The aqueous phase was extracted with further DCM (2 x 50ml) and the combined organic extracts dried (sodium sulphate) and concentrated in vacuo to give a pale yellow solid (14.6g, 85%)

- 25 The reaction mixture was diluted with water (100ml) and the organic phase separated. The aqueous phase was extracted with further DCM (2 x 50ml) and the combined organic extracts dried (sodium sulphate) and concentrated in vacuo to give a pale yellow solid (14.6g, 85%)

¹H NMR (400MHz, CDCl₃): δ 7.39-7.29 (5H, m), 5.13 (2H, s), 4.58 (1H, m), 4.19 (1H, m), 3.66 (1H, m), 3.49 (1H, m), 3.25 (1H, m), 2.14 (1H, m), 1.82 (1H, m), 1.44 (9H, s) ppm.

- 30 MS (ESI) *m/z* 321 [M+H]⁺

Preparation 46 : Benzyl (3R)-3-[(*tert*-butoxycarbonyl)amino]pyrrolidine-1-carboxylate




- 35 A solution of the carbamate of preparation 45 (14.6g, 45.6mmol) in THF (85ml) was cooled to 0°C and treated with potassium *tert*-butoxide (4.38g, 59.27mmol). The reaction was left to stir for 30 minutes prior

to the addition of methyl iodide (4.26ml, 59.3mmol) and then allowed to warm gradually to room temperature. The reaction mixture was partitioned between ethyl acetate (200ml) and water (100ml). The aqueous phase was separated and extracted with further ethyl acetate (100ml). The combined organic extracts were washed with saturated aqueous sodium chloride (100ml), dried (magnesium sulphate) and reduced in vacuo to give an orange oil. The oil was re-dissolved in THF (85ml), cooled to 0°C and treated with potassium *tert*-butoxide (3.00g, 40.6mmol). The reaction was left to stir for 30 minutes prior to the addition of methyl iodide (3.0ml, 41.7mmol) and then allowed to warm gradually to room temperature. The reaction mixture was partitioned between ethyl acetate (200ml) and water (100ml). The aqueous phase was separated and extracted with further ethyl acetate (100ml). The combined organic extracts were washed with saturated aqueous sodium chloride (100ml), dried (magnesium sulphate) and reduced in vacuo to give the title compound as an orange oil (15.3g, 100%).

¹H NMR (400MHz, CDCl₃): δ 7.35-7.26 (5H, m), 5.11 (2H, s), 4.70 (1H, m), 3.58 (2H, m), 3.34 (1H, m), 3.29 (1H, m), 2.74 (3H, s), 1.98 (2H, m), 1.43 (9H, s) ppm.

MS (ESI) m/z 335 [M+H]⁺

Preparation 47 : *tert*-Butyl methyl[(3R)-pyrrolidin-3-yl]carbamate




A solution of the carbamate of preparation 46 (15.58g, 46.6mmol) in ethanol (150ml) was hydrogenated in the presence of 5%Pd/C (1g) at 50psi at room temperature for a period of 18 hours. Further Pd/C (500mg) was added and the resulting mixture hydrogenated under the same conditions for a further 26 hours. The catalyst was filtered off and the filtrate concentrated in vacuo. Purification by chromatography (DCM:MeOH:0.880 ammonia (100:0:0 changing to 90:10:1 by volume) gave the title compounds as a pale yellow oil (5.85g, 62%).

¹H NMR (400MHz, CDCl₃): δ 4.56 (1H, m), 3.06 (2H, m), 2.87 (1H, m), 2.79 (1H, m), 2.78 (3H, s), 2.54 (1H, s), 1.95 (1H, m), 1.73 (1H, m), 1.43 (9H, s) ppm.

MS (ESI) m/z 201 [M+H]⁺

Example 1: *N*-(3,3-Dimethylbutyl)-6-(4-methylpiperazin-1-yl)pyrimidin-4-amine




A solution of the title compound (110 mg, 0.52 mmol) of preparation 6 in NMP (2 mL) was treated with DIPEA (135 µL, 0.78 mmol) and 3,3-dimethylbutan-1-amine (347 µL, 2.6 mmol) and heated to 150 °C for 18 hours in a sealed vessel. The reaction mixture was cooled to ambient temperature and partitioned between ethyl acetate (20 mL) and water (20 mL). The organic fraction was washed with saturated aqueous sodium chloride (20 mL) dried (MgSO₄) and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel eluting with DCM : MeOH : 0.880 ammonia (90 : 10 : 1 by volume) to yield the title compound as a gum (57mg, 40%).

¹H NMR (400MHz, CD₃OD): δ 7.95 (1H, s), 5.56 (1H, s), 3.51 (4H, m), 3.23 (2H, m), 2.47 (4H, m), 2.30 (3H, s), 1.49 (2H, m), 0.95 (9H, s) ppm.

MS (APCI) m/z 278 [M+H]⁺


Examples 2 to 5

- 5 The following compounds were prepared by a method similar to that described for example 1 using the appropriate starting material.



No.	Preparation No. of Starting material.	NR ² R ³	Name	Yield	LRMS m/z
2	3		6-[(3S)-3-(Dimethylamino)pyrrolidin-1-yl]-N-(3,3-dimethylbutyl)pyrimidin-4-amine	20%	292
3	4		N-(3,3-Dimethylbutyl)-6-[(3aR*,6aS*)-5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]pyrimidin-4-amine	24%	304
4	5		6-[3-(Dimethylamino)azetidin-1-yl]-N-(3,3-dimethylbutyl)pyrimidin-4-amine	41%	278
5	7		N-(3,3-Dimethylbutyl)-6-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]pyrimidin-4-amine	3%	290

Example 6: N-(3,3-Dimethylbutyl)-N'-[(3S)-pyrrolidin-3-yl]pyrimidine-4,6-diamine



10

A solution of the compound of preparation 20 (2.15 g, 6.1 mmol) in EtOH (40 mL) and MeOH (20 mL) was cooled to 0 °C and treated with palladium hydroxide (20% on carbon 100 mg) followed by ammonium formate (5.8 g, 91 mmol) and heated to reflux for 2 hours. The reaction mixture was cooled to ambient temperature filtered and the filtrate concentrated *in vacuo*. The residue was purified directly by SCX resin, eluting non-basic compounds with MeOH and the basic compounds with 1N ammonia in MeOH.


15

The basic washings were concentrated *in vacuo* and purified by flash column chromatography on silica gel eluting with DCM : MeOH : 0.880 ammonia (1 : 0 : 0 changing to 80 : 20 : 1, by volume) to yield the title compound as a white powdery solid (1.2 g, 75%).

¹H NMR (400MHz, CD₃OD): δ 7.9 (1H, s), 5.4 (1H, s), 4.1 (1H, m), 3.2 (2H, m), 3.1 (1H, m), 3.0 (1H, m), 2.9 (1H, m), 2.7 (1H, m), 2.1 (1H, m), 1.7 (1H, m), 1.5 (2H, m), 1.0 (9H, s) ppm.

Accurate mass: found 264.2181, C₁₄H₂₆N₅ requires 264.2183.

Example 7: N-(3,3-Dimethylbutyl)-N'-[(3R)-pyrrolidin-3-yl]pyrimidine-4,6-diamine




The title compound was prepared by a similar method to that described for example 6, using the title compound of preparation 21, in 70% yield.

¹H NMR (400MHz, CD₃OD): δ 7.9 (1H, s), 5.4 (1H, s), 4.1 (1H, m), 3.2 (2H, m), 3.1 (1H, m), 3.0 (1H, m), 2.9 (1H, m), 2.7 (1H, m), 2.1 (1H, m), 1.7 (1H, m), 1.5 (2H, m), 1.0 (9H, s) ppm.

MS (APCI) m/z 264 [M+H]⁺

Example 8: N-(3,3-Dimethylbutyl)-N'-[(3R)-1-methylpyrrolidin-3-yl]pyrimidine-4,6-diamine




A suspension of the compound of example 7 (38 mg, 0.144 mmol) in THF (1.5 mL) containing aqueous formaldehyde (11 μL, 0.144 mmol, 37% in water) and acetic acid (8.3 μL, 0.144 mmol) was treated with sodium triacetoxyborohydride (37 mg, 0.173 mmol) and stirred at ambient temperature for 10 min. The reaction mixture was applied directly to SCX resin, eluting non-basic compounds with MeOH and the basic compounds with 1N ammonia in MeOH. The basic washings were concentrated *in vacuo* and purified by flash column chromatography on silica gel eluting with DCM : MeOH : 0.880 ammonia (1 : 0 : 0 changing to 40 : 10 : 1, by volume) further purification on reverse phase silica eluting with water : acetonitrile (1 : 0 changing to 19 : 1 by volume) gave the title compound as a white solid (14 mg, 35%).

¹H NMR (400MHz, CD₃OD): δ 7.9 (1H, s), 5.4 (1H, s), 4.2 (1H, m), 3.2 (2H, m), 2.9 (1H, m), 2.8 (1H, m), 2.5 (2H, m), 2.4 (4H, m), 1.7 (1H, m), 1.5 (2H, m), 1.1 (9H, s) ppm.

MS (APCI) m/z 278 [M+H]⁺, 276 [M-H]⁻

Example 9: N⁴-(Cyclopropylmethyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine

43




A solution of the compound of preparation 15 (120 mg, 0.38 mmol) in NMP (2 mL) was treated with DIPEA (191 μ L, 1.1 mmol) and 1-cyclopropylmethylamine (99 μ L, 1.15 mmol) and heated to 150 $^{\circ}$ C in a sealed vessel for 18 hours. The reaction mixture was diluted with ethyl acetate (50 mL) and washed with water (4 x 50 mL) and saturated aqueous sodium chloride (50 mL), dried (MgSO_4) and concentrated *in vacuo* to give the crude intermediate *tert*-butyloxycarbonyl-protected compound. This crude material was dissolved in DCM (2 mL), treated with trifluoroacetic acid (2 mL) and stirred at ambient temperature for 3 h after which time the reaction mixture was concentrated *in vacuo*. The residue was purified directly by SCX resin, eluting non-basic compounds with MeOH and the basic compounds with 2 N ammonia in MeOH. The basic washings were concentrated *in vacuo* and purified by flash column chromatography on silica gel eluting with DCM : MeOH : 0.880 ammonia (1 : 0 : 0 changing to 170 : 30 : 3, by volume) to yield the title compound as a white foam (16 mg, 17%).

^1H NMR (400MHz, CD_3OD): δ 4.89 (1H, s), 3.63 (1H, m), 3.55 (1H, m), 3.47 (1H, m), 3.39 (1H, m), 3.23 (1H, m), 3.05 (2H, d), 2.42 (3H, s), 2.21 (1H, m), 1.88 (1H, m), 1.06 (1H, m), 0.52 (2H, q), 0.23 (2H, q) ppm.

MS (APCI) m/z 248 $[\text{M}+\text{H}]^+$

Alternative method for example 9: N^4 -(Cyclopropylmethyl)-6-[(3*R*)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine



A suspension of the compound of preparation 15 (1.8g, 5.5mmol) in cyclopropylmethanamine (5.4ml, 62.3mmol) and TEA (1.53ml, 11mmol) was heated in a sealed pressure vessel at 120 $^{\circ}$ C for 24 hours. The excess amine was removed *in vacuo* and the residue partitioned between water (100ml) and DCM (100ml). The aqueous phase was separated and extracted with further DCM (100ml). The combined organic extracts were washed with saturated aqueous sodium chloride (100ml) and the solvent removed *in vacuo*. Purification by flash column chromatography on silica gel eluting with DCM : MeOH : 0.880 ammonia (98 : 2 : 0 changing to 95 : 5 : 0.2, by volume) gave the to give the intermediate *tert*-butyloxycarbonyl-protected compound (1.55g, 77%).


^1H NMR (400MHz, CD_3OD): δ 4.89 (1H, s), 4.71 (1H, m), 3.64 (2H, m), 3.32 (2H, m), 3.07 (2H, d), 2.80 (3H, s), 2.13 (2H, m), 1.46 (9H, s), 1.05 (1H, m), 0.52 (2H, m), 0.23 (2H, m) ppm.

MS (APCI) m/z 363 $[\text{M}+\text{H}]^+$

A solution of the intermediate *tert*-butyloxycarbonyl-protected compound (6.18g, 16.6mmol) in methanol (15ml) was treated with 4M HCl in 1,4-dioxan (42ml, 168mmol) and the resulting solution was left to stir at room temperature (exotherm observed on addition of the HCl) for 18 hours. The solvent was removed in

vacuo and the residue partitioned between 0.880 ammonia (50ml) and DCM (400ml). The aqueous phase was separated and extracted with further DCM (200ml). The combined organic extracts were dried (sodium sulphate) and the solvent removed in vacuo to give a pale yellow oil (4.00g, 92%).

5 **Example 9a : N⁴-(Cyclopropylmethyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine L-tartrate**




A solution of the compound of example 9 (10.14g, 38.65mmol) in methanol (340ml) was treated with a solution of L-(+) tartaric acid in (5.8g, 38.65mmol) in methanol (50ml). The resulting suspension was stirred at room temperature for 30 minutes and the resulting solid filtered off and dried in vacuo. The solid was dissolved in the minimum volume of boiling water (22ml) and then methanol was added until a permanent ppt was observed (102ml). The resulting suspension was allowed to cool gradually to room temperature and the solid filtered and dried in vacuo for 50°C for 3 days and then allowed to equilibrate at room temperature in air for a further 2 days to give the title compounds as a colourless solid (14.15g, 89%)

¹H NMR (400MHz, CD₃OD): δ 6.41 (1H, br s), 5.72 (2H, br s), 4.81 (1H, s), 3.92 (2H, s), 3.58 (2H, m), 3.40 (1H, m), 3.32 (2H, m), 3.03 (2H, m), 2.48 (3H, s), 2.18 (1H, m), 1.95 (1H, m), 0.96 (1H, m), 0.39 (2H, m), 0.12 (2H, m) ppm.

MS (APCI) m/z 263 [M+H]⁺

20 **Examples 10 to 12**


The following compounds were prepared by a method similar to that described for example 9 using the title compound of preparation 15 and the appropriate amine starting material.



No.	R ¹	Name	Yield	LRMS m/z
10		N ⁴ -Isobutyl-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine	24%	265
11		N ⁴ -(2,2-Dimethylpropyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine	34%	279
12	Et	N ⁴ -Ethyl-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine	27%	237

Examples 13 to 15


The following compounds were prepared by a method similar to that described for example 9, using the compound of preparation 10 and the appropriate amine starting material.




No.	R ¹	Name	Yield	LRMS m/z
13	Et	N-Ethyl-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine	64%	222
14		N-Isobutyl-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine	32%	250
15		N-(Cyclopropylmethyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine	17%	248

5 **Examples 16 to 17**

The following compounds were prepared by a method similar to that described for example 9 using the compound of preparation 11 and the appropriate amine starting material.



No.	R ¹	Name	Yield	LRMS m/z
16	Et	N-Ethyl-6-[(3S)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine	28%	222
17		N-(3,3-Dimethylbutyl)-6-[(3S)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine	26%	278

10 **Example 18: 6-[(3R)-3-(Dimethylamino)pyrrolidin-1-yl]-N-(3,3-dimethylbutyl)pyrimidin-4-amine**

- 15 A solution of the title compound of preparation 2 (120 mg, 0.53 mmol) in NMP (2 mL) was treated with DIPEA (276 μ L 1.59 mmol) 3,3-dimethylbutan-1-amine (213 μ L, 1.59 mmol) and heated to 150 °C in a sealed vessel for 72 hours. The reaction mixture was cooled and purified directly by SCX resin, eluting non-basic compounds with MeOH and the basic compounds with 2 N ammonia in MeOH. The basic washings were concentrated *in vacuo* and purified by flash column chromatography on silica gel eluting


with DCM : MeOH : 0.880 ammonia (1 : 0 : 0 changing to 40 : 10 : 1, by volume) to yield the title compound as a gum (72 mg, 47%).

¹H NMR (400MHz, CD₃OD): δ 7.92 (1H, s), 5.30 (1H, s), 3.72 (1H, m), 3.61 (1H, m), 3.37 (1H, m), 3.24 (2H, m), 3.17 (1H, m), 2.89 (1H, m), 2.32 (6H, s), 2.25 (1H, m), 1.87 (1H, m), 1.52 (2H, m), 0.98 (9H, s) ppm.

MS (APCI) m/z 292 [M+H]⁺


Examples 19 to 22

The following compounds were prepared by a method similar to that described for example 18 using the title compound of preparation 2.



No.	R ¹	Name	Yield	LRMS m/z
19		N-(Cyclopropylmethyl)-6-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]pyrimidin-4-amine	64%	262
20		6-[(3R)-3-(Dimethylamino)pyrrolidin-1-yl]-N-isobutylpyrimidin-4-amine	60%	264
21	Et	6-[(3R)-3-(Dimethylamino)pyrrolidin-1-yl]-N-ethylpyrimidin-4-amine	55%	236
22		6-[(3R)-3-(Dimethylamino)pyrrolidin-1-yl]-N-(2,2-dimethylpropyl)pyrimidin-4-amine	41%	278


Example 23: N⁴-(3,3-Dimethylbutyl)-6-[(4aR*,7aR*)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine



The title compound of preparation 24 (45 mg, 0.11 mmol) was dissolved in trifluoroacetic acid (2 mL) and stirred at ambient temperature for 1 hour after which time the reaction mixture was concentrated *in vacuo*. The residue was purified directly by SCX resin, eluting non-basic compounds with MeOH and the basic compounds with 1 N ammonia in MeOH taking 4 mL fractions to yield the title compound as a solid (25 mg, 71%).

¹H NMR (400MHz, CD₃OD): δ 3.52 - 3.33 (5H, m), 3.22 - 3.14 (2H, m), 2.97 - 2.86 (1H, m), 2.66 - 2.57 (1H, m), 2.40 - 2.29 (1H, m), 1.80 - 1.72 (2H, m), 1.70 - 1.55 (1H, m), 1.53 - 1.43 (3H, m), 0.97 (9H, s) ppm.

MS (ESI) m/z 319 [M+H]⁺

Example 24: N⁴-Isopropyl-6-[(4aR*,7aR*)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine


The title compound was prepared by a method similar to that described for example 23 and preparation 24, by reaction of the compound of preparation 14 with isopropyl amine and subsequent deprotection, in 28% yield.

¹H NMR (400MHz, CD₃OD): δ 4.77 (1H, s), 3.86 - 3.74 (1H, m), 3.51 - 3.34 (5H, m) 2.96 - 2.86 (1H, m), 2.66 - 2.56 (1H, m), 2.40 - 2.26 (1H, m), 1.81 - 1.72 (2H, m), 1.70 - 1.57 (1H, m), 1.54 - 1.41 (1H, m), 1.18 (6H, d) ppm


MS (ESI) m/z 277 [M+H]⁺

Examples 25 to 33


The following compounds were prepared by a method similar to that described for example 23 and preparation 24 by reaction of the compound of preparation 14 with an appropriate amine and subsequent deprotection.



No.	R ¹	Name	Yield	LRMS m/z
25	Me	N ⁴ -Methyl-6-[(4aR*,7aR*)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine	36%	249
26	Et	N ⁴ -Ethyl-6-[(4aR*,7aR*)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine	11%	263
27		N ⁴ -Isobutyl-6-[(4aR*,7aR*)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine	32%	291
28		N ⁴ -(Cyclopropylmethyl)-6-[(4aR*,7aR*)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine	39%	289
29		N ⁴ -(3-Methylbutyl)-6-[(4aR*,7aR*)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine	62%	305
30		N ⁴ -(2,2-Dimethylpropyl)-6-[(4aR*,7aR*)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine	29%	305
31		N ⁴ -Cyclopropyl-6-[(4aR*,7aR*)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine	19%	275
32		N ⁴ -Cyclobutyl-6-[(4aR*,7aR*)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine	43%	289

33		N ⁴ -(Cyclopentylmethyl)-6-[(4aR*,7aR*)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine	11%	317
----	---	---	-----	-----


Example 34: 6-[(3aR*,6aS*)-5-Methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-N⁴-propylpyrimidine-2,4-diamine





- 5 To a solution of the title compound of preparation 13 (20 mg, 0.08 mmol) in DMSO (75 μ L) was added propylamine (75 μ L, 1 mmol) and the mixture was heated to 120 °C in a sealed vessel for 48 hours. The reaction mixture was concentrated *in vacuo* to give a brown gum. The residual gum was purified by flash column chromatography on silica gel eluting with DCM : MeOH : 0.880 ammonia (990 : 10 : 1 changing to 90 : 10 : 1, by volume) to yield the title compound as a gum (10 mg; 45%).
- 10 ¹H NMR (400MHz, CD₃COCD₃): δ 5.28 (1H, br t), 4.97 (3H, m), 3.51 (2H, m), 3.20 (4H, m), 2.83 (1H, m), 2.51 (2H, m), 2.41 (2H, m), 2.22 (3H, s) 1.56 (2H, m), 0.92 (3H, t) ppm
- MS (ESI) m/z 277 [M+H]⁺


Examples 35 to 43

- The following compounds were prepared by a method similar to that described for example 34 using the compound of preparation 13 and the appropriate amine starting material.
- 15



No.	R ¹	Name	Yield	LRMS m/z
35	Me	N ⁴ -Methyl-6-[(3aR*,6aS*)-5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]pyrimidine-2,4-diamine	30%	249
36	Et	N ⁴ -Ethyl-6-[(3aR*,6aS*)-5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]pyrimidine-2,4-diamine	62%	263
37		N ⁴ -Isobutyl-6-[(3aR*,6aS*)-5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]pyrimidine-2,4-diamine	52%	291
38		N ⁴ -(Cyclopropylmethyl)-6-[(3aR*,6aS*)-5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]pyrimidine-2,4-diamine	78%	289
39		N ⁴ -(2,2-Dimethylpropyl)-6-[(3aR*,6aS*)-5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]pyrimidine-2,4-diamine	46%	305


		yl]pyrimidine-2,4-diamine		
40		N ⁴ -(3,3-Dimethylbutyl)-6-[(3aR*,6aS*)-5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]pyrimidine-2,4-diamine	48%	319
41		N ⁴ -(3-Methylbutyl)-6-[(3aR*,6aS*)-5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]pyrimidine-2,4-diamine	54%	305
42		N ⁴ -Cyclopropyl-6-[(3aR*,6aS*)-5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]pyrimidine-2,4-diamine	27%	275
43		N ⁴ -Cyclobutyl-6-[(3aR*,6aS*)-5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]pyrimidine-2,4-diamine	48%	289

Example 44: Cyclopropylmethyl-[6-(3-methylamino-azetidin-1-yl)-pyrimidin-4-yl]-amine

A solution of the title compound of preparation 22 (70 mg, 0.21 mmol) in DCM (5 mL) was treated with trifluoroacetic acid (0.5 mL) and stirred at ambient temperature for 2 hours after which time the reaction mixture was concentrated *in vacuo*. The residue was purified directly by SCX resin, eluting non-basic compounds with MeOH and the basic compounds with 2 N ammonia in MeOH taking 20 mL fractions to yield the title compound (45 mg, 92%).

¹H NMR (400MHz, CDCl₃): δ 8.12 (1H, s), 5.06 (1H, s), 4.89 (1H, br s), 4.20 (2H, m), 3.71 (3H, m), 3.03 (2H, m), 2.42 (3H, s), 1.05 (1H, m), 0.54 (2H, m), 0.24 (2H, m) ppm.

Accurate mass: found 234.1709, C₁₂H₂₀N₅ requires 234.1719.

Example 45: (3-Fluoro-benzyl)-[6-(3-methylamino-azetidin-1-yl)-pyrimidin-4-yl]-amine


A solution of the title compound of preparation 23 (42 mg, 0.11 mmol) in DCM (5 mL) was treated with trifluoroacetic acid (0.5 mL) and stirred at ambient temperature for 2 hours after which time the reaction mixture was concentrated *in vacuo*. The residual oil was purified by flash column chromatography on silica gel eluting with DCM : MeOH : 0.880 ammonia (1 : 0 : 0 changing to 182 : 15 : 3, by volume) to yield the title compound as a solid (29 mg, 94%).

¹H NMR (400MHz, CDCl₃): δ 8.17 (1H, s), 7.29 (1H, m), 7.09 (1H, d), 7.02 (1H, d), 6.97 (1H, m), 5.07 (1H, d), 5.02 (1H, br s), 4.45 (2H, d), 4.16 (2H, m), 3.69 (3H, m), 2.42 (3H, s) ppm.

MS (APCI) m/z 288 [M+H]⁺

Examples 46 to 59


The following compounds were prepared by a method similar to that described for example 44 and preparation 22, by reaction of the compound of preparation 1 with an appropriate amine and subsequent deprotection.




5

No.	R ⁴ R ¹ N	Name	Yield	LRMS m/z
46	iPrNH	N-Isopropyl-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine	74%	222
47		N-(4-Fluorobenzyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine	38%	288
48	EtNH	N-Ethyl-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine	92%	208
49		N-Isobutyl-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine	12%	236
50	HO-CH ₂ -CH ₂ -NH	2-({6-[3-(Methylamino)azetidin-1-yl]pyrimidin-4-yl}amino)ethanol	41%	224
51		N-Benzyl-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine	27%	270
52		N-(2-Chlorobenzyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine	42%	304
53		N-Methyl-1-[6-(4-methylpiperidin-1-yl)pyrimidin-4-yl]azetidin-3-amine	46%	262
54		N-(2-Methoxyethyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine	77%	238
55		6-[3-(Methylamino)azetidin-1-yl]-N-(3-methylbutyl)pyrimidin-4-amine	85%	250
56		N-Methyl-1-(6-piperidin-1-ylpyrimidin-4-yl)azetidin-3-amine	45%	248
57		N-(2,2-Dimethylpropyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine	84%	250
58	MeNH	N-Methyl-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine	88%	195

51


59		N-(3,3-Dimethylbutyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine	81%	264
----	---	---	-----	-----

Example 60: N⁴-Isopropyl-6-(3-methylamino-azetidin-1-yl)-pyrimidine-2,4-diamine

The title compound of preparation 26 (22 mg, 0.07 mmol) was dissolved in trifluoroacetic acid (1 mL) and stirred at ambient temperature for 2 hours after which time the reaction mixture was concentrated *in vacuo*. The residual gum was purified by flash column chromatography on silica gel eluting with DCM : MeOH : 0.880 ammonia (98 : 2 : 0.2 changing to 90 : 10 : 1, by volume) to yield the title compound as a gum (12mg, 73%).

¹H NMR (400MHz, CD₃OD): δ 4.74 (1H, s), 4.1 (2H, dd), 3.82 (1H, m), 3.67 (2H, m), 3.61 (1H, m), 2.33 (3H, s), 1.16 (6H, d) ppm.


MS (APCI) m/z 237 [M+H]⁺

Example 61: N⁴-(2,2-Dimethylpropyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine

The title compound was prepared by a method similar to that described for example 60, using the compound of preparation 25, in 91% yield.

¹H NMR (400MHz, CD₃COCD₃): δ 5.29 (1H, br t), 4.97 (2H, br s), 4.79 (1H, s), 3.97 (2H, t), 3.56 – 3.49 (3H, m), 3.08 (2H, br d), 2.32 (3H, s), 0.93 (9H, s) ppm

MS (ESI) m/z 265 [M+H]⁺

Example 62: 6-(3-Methylamino-azetidin-1-yl)-N⁴-(3,3,3-trifluoro-propyl)-pyrimidine-2,4-diamine


The title compound was prepared by a method similar to that described for example 60, using the compound of preparation 27, in 92% yield.

¹H NMR (400MHz, CD₃OD): δ 4.78 (1H, s), 4.11 (2H, m), 3.68 (2H, dd), 3.62 (1H, m), 3.48 (2H, t), 2.42 (2H, m), 2.34 (3H, s) ppm

MS (ESI) m/z 291 [M+H]⁺

Example 63: N⁴-Cyclopropylmethyl-6-(3-methylamino-azetidin-1-yl)-pyrimidine-2,4-diamine

52




The title compound was prepared by a method similar to that described for example 60, using the compound of preparation 28, in 85% yield.

¹H NMR (400MHz, CD₃OD): δ 4.17 (2H, m), 3.76 (2H, m), 3.70 (1H, m), 3.06 (2H, d), 2.39 (3H, s), 1.01 (1H, m), 0.52 (2H, m), 0.22 (2H, m) ppm.

MS (APCI) m/z 249 [M+H]⁺

Example 64: N⁴-(3,3-Dimethyl-butyl)-6-(3-methylamino-azetidin-1-yl)-pyrimidine-2,4-diamine




The title compound was prepared by a method similar to that described for example 60, using the compound of preparation 29, in 87% yield.

¹H NMR (400MHz, CD₃OD): δ 4.73 (1H, s), 4.11 (2H, m), 3.68 (2H, m), 3.62 (1H, m), 3.18 (2H, m), 2.33 (3H, s), 1.48 (2H, m), 0.96 (9H, s) ppm.

MS (APCI) m/z 279 [M+H]⁺

Example 65: N⁴-(3-Fluoro-benzyl)-6-(3-methylamino-azetidin-1-yl)-pyrimidine-2,4-diamine




The title compound was prepared by a method similar to that described for example 60, using the compound of preparation 30, in 84% yield.

¹H NMR (400MHz, CD₃COCD₃): δ 7.32 (1H, m), 7.16 (1H, d), 7.10 (1H, br d), 6.96 (1H, m), 6.01 (1H, m), 5.06 (2H, br s), 4.79 (1H, s), 4.51 (2H, d), 3.96 (2H, t), 3.57 – 3.48 (3H, m), 2.31 (3H, s) ppm.

MS (APCI) m/z 303 [M+H]⁺

Example 66: N⁴-(3-Methoxy-benzyl)-6-(3-methylamino-azetidin-1-yl)-pyrimidine-2,4-diamine




The title compound was prepared by a method similar to that described for example 60, using the compound of preparation 31, in 72% yield.

53

¹H NMR (400MHz, CD₃OD): δ 7.20 (1H, t), 6.89 – 6.85 (2H, m), 6.78 (1H, dd), 4.73 (1H, s), 4.37 (2H, s), 4.07 (2H, t), 3.76 (3H, s), 3.65 – 3.55 (3H, m), 2.31 (3H, s) ppm.

MS (APCI) m/z 315 [M+H]⁺

5 **Example 67: N⁴-Cyclobutylmethyl-6-(3-methylamino-azetidin-1-yl)-pyrimidine-2,4-diamine**




The title compound was prepared by a method similar to that described for example 60, using the compound of preparation 32, in 86% yield.

10 ¹H NMR (400MHz, CD₃COCD₃): δ 5.31 (1H, m), 4.99 (2H, br s), 4.73 (1H, s), 3.96 (2H, t), 3.58 – 3.50 (3H, m), 3.23 (2H, t), 2.55 (1H, m), 2.32 (3H, s), 2.05 – 1.97 (H, m), 1.90 – 1.82 (2H, m), 1.77 – 1.68 (2H, m) ppm.

MS (APCI) m/z 263 [M+H]⁺

Example 68: N⁴-Cyclopentylmethyl-6-(3-methylamino-azetidin-1-yl)-pyrimidine-2,4-diamine



15


The title compound was prepared by a method similar to that described for example 60, using the compound of preparation 33, in 81% yield.

¹H NMR (400MHz, CD₃OD): δ 4.75 (1H, s), 4.11 (2H, dd), 3.68 (2H, dd), 3.61 (1H, m), 3.09 (2H, d), 2.33 (3H, s), 2.13 (1H, m), 1.83 – 1.75 (2H, m), 1.70 – 1.53 (4H, m), 1.29 – 1.21 (2H, m) ppm.

20 MS (APCI) m/z 277 [M+H]⁺











Examples 69 to 90







The following compounds were prepared by a method similar to that described for example 60 and preparation 26 by reaction of the compound of preparation 12 with an appropriate amine and subsequent deprotection.




25

No	R ¹	Name	Yield	LRMS m/z
69	Me	N ⁴ -Methyl-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine	78%	209

70	Et	N ⁴ -Ethyl-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine	83%	223
71		N ⁴ -Isobutyl-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine	87%	251
72		N ⁴ -Cyclopropyl-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine	74%	235
73		6-[3-(Methylamino)azetidin-1-yl]-N ⁴ -propylpyrimidine-2,4-diamine	85%	237
74		6-[3-(Methylamino)azetidin-1-yl]-N ⁴ -(3-methylbutyl)pyrimidine-2,4-diamine	81%	265
75		N ⁴ -Cyclobutyl-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine	72%	249
76		6-[3-(Methylamino)azetidin-1-yl]-N ⁴ -[4-(trifluoromethoxy)benzyl]pyrimidine-2,4-diamine	76%	369
77		4-[[{(2-Amino-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-yl)amino)methyl]benzonitrile	79%	310
78		N ⁴ -(2-Fluorobenzyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine	77%	303
79		N ⁴ -Benzyl-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine	65%	285
80		6-[3-(Methylamino)azetidin-1-yl]-N ⁴ -[3-(trifluoromethyl)benzyl]pyrimidine-2,4-diamine	81%	353
81		N ⁴ -(4-Chlorobenzyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine	73%	319
82		6-[3-(Methylamino)azetidin-1-yl]-N ⁴ -(2-methylbenzyl)pyrimidine-2,4-diamine	68%	299
83		6-[3-(Methylamino)azetidin-1-yl]-N ⁴ -(3-methylbenzyl)pyrimidine-2,4-diamine	79%	299
84		6-[3-(Methylamino)azetidin-1-yl]-N ⁴ -(2-(trifluoromethyl)benzyl)pyrimidine-2,4-diamine	74%	353

85		6-[3-(Methylamino)azetidin-1-yl]-N ⁴ -(4-(trifluoromethyl)benzyl)pyrimidine-2,4-diamine	77%	353
86		N ⁴ -(3-Chlorobenzyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine	71%	319
87		N ⁴ -(2-Methoxybenzyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine	68%	315
88		6-[3-(Methylamino)azetidin-1-yl]-N ⁴ -(4-methylbenzyl)pyrimidine-2,4-diamine	70%	299
89		N ⁴ -(2-Chlorobenzyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine	72%	319
90		N ⁴ -(4-Fluorobenzyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine	83%	303

Example 91: N⁴-(3-Fluorobenzyl)-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine



- 5 The title compound of preparation 18 (20 mg, 0.08 mmol) was treated with DMSO (150 μ L) and N-methylpiperazine (88 μ L, 0.79 mmol) and heated to 120 °C in a sealed vessel for 16 hours. The reaction mixture was cooled to ambient temperature, partitioned between water (2 mL) and ethyl acetate (2 mL) and filtered through diatomaceous earth, washing with further ethyl acetate (15 mL). The organic fraction of the filtrate was concentrated *in vacuo* and purified by flash column chromatography on silica gel eluting with DCM : MeOH : 0.880 ammonia (90 : 10 : 1 changing to 90 : 10 : 1, by volume) to yield the title compound as a gum (20 mg, 79%).


¹H NMR (400MHz, CD₃OD): δ 7.34 - 7.27 (1H, m), 7.14 - 7.10 (1H, m), 7.08 - 7.01 (1H, m), 6.98 - 6.89 (1H, m), 5.11 (1H, s), 4.45 (2H, s), 3.51 - 3.42 (4H, m), 2.48 - 2.41 (4H, m), (2.30 (3H, s) ppm.

MS (APCI) *m/z* 208 [M-C₇H₆F₁+2H]⁺


15 **Examples 92 to 98**

The following compounds were prepared by a method similar to that described for example 91 using the appropriate pyrimidine starting material and the appropriate amine starting material.

56












No.	R ¹ NH	NR ² R ³	Name	Yield	Preparation No. of Starting material	LR MS m/z
92			N ⁴ -(3-Fluorobenzyl)-6- [(3aR*,6aS*)-5- methylhexahydropyrrol o[3,4-c]pyrrol-2(1H)- yl]pyrimidine-2,4- diamine	73%	18	343
93			N ⁴ -(3,3-Dimethylbutyl)- 6-[(3R)-3- methylpiperazin-1- yl]pyrimidine-2,4- diamine	92%	16	293
94			N ⁴ -(3,3-Dimethylbutyl)- 6-[(3S)-3- methylpiperazin-1- yl]pyrimidine-2,4- diamine	89%	16	293
95			N ⁴ -(2,2- Dimethylpropyl)-6- [(3R)-3- methylpiperazin-1- yl]pyrimidine-2,4- diamine	85%	19	279
96			N ⁴ -(2,2- Dimethylpropyl)-6- [(3S)-3- methylpiperazin-1- yl]pyrimidine-2,4- diamine	77%	19	279
97	EtNH		N ⁴ -Ethyl-6-[(3R)-3- methylpiperazin-1- yl]pyrimidine-2,4- diamine	85%	17	237













98	EtNH		N ⁴ -Ethyl-6-[(3S)-3-methylpiperazin-1-yl]pyrimidine-2,4-diamine	73%	17	237
----	------	---	---	-----	----	-----









Examples 99 to 127

The following compounds were prepared by similar method to those used to prepare the compounds above.

5


No.	Structure	Name	LRMS m/z
99		N-(2,2-Dimethylpropyl)-6-(4-methylpiperazin-1-yl)pyrimidin-4-amine	264
100		N-(3-Methylbutyl)-6-(4-methylpiperazin-1-yl)pyrimidin-4-amine	264
101		N ⁴ -(3,3-Dimethylbutyl)-N ⁶ -[(3S)-pyrrolidin-3-yl]pyrimidine-2,4,6-triamine	279
102		N ⁴ -(3,3-Dimethylbutyl)-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine	293
103		N-Ethyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-amine	222
104		N ⁴ -Isopropyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-amine	236
105		N-Isobutyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-amine	250
106		N-(Cyclopropylmethyl)-6-(4-methylpiperazin-1-yl)pyrimidin-4-amine	248
107		N-(3-Methylbutyl)-N ⁶ -[(3S)-pyrrolidin-3-yl]pyrimidine-4,6-diamine	250

108		N-(3-Methylbutyl)-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine	279
109		N-(3,3-Dimethylbutyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine	278
110		N-(2-Methoxyethyl)-6-(4-methylpiperazin-1-yl)pyrimidin-4-amine	252
111		N-(3,3-Dimethylbutyl)-6-piperazin-1-ylpyrimidin-4-amine	264
112		6-(4-Methylpiperazin-1-yl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]pyrimidin-4-amine	278
113		6-(4-Methylpiperazin-1-yl)-N-[(2R)-tetrahydrofuran-2-ylmethyl]pyrimidin-4-amine	278
114		4-(4-Methylpiperazin-1-yl)-6-pyrrolidin-1-ylpyrimidine	248
115		6-(4-Methylpiperazin-1-yl)-N-(3,3,3-trifluoropropyl)pyrimidin-4-amine	290
116		N-Isobutyl-5-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-amine	263
117		N-Ethyl-6-[(3aR*,6aS*)-5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]pyrimidin-4-amine	248
118		6-(3-Aminoazetidin-1-yl)-N-(3,3-dimethylbutyl)pyrimidin-4-amine	250
119		N'-Isopropyl-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine	251


120		N ⁴ -Ethyl-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine	237
121		N ⁴ -Isobutyl-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine	265
122		N ⁴ -(Cyclopropylmethyl)-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine	263
123		N-(Cyclopropylmethyl)-6-[(4aR*,7aR*)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidin-4-amine	274
124		N ⁴ -(3,3-Dimethylbutyl)-6-[(3R)-3,4-dimethylpiperazin-1-yl]pyrimidine-2,4-diamine	307
125		N-Isobutyl-6-[(4aR*,7aR*)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidin-4-amine	276
126		6-[(1R*,5S*,6s*)-6-Amino-3-azabicyclo[3.1.0]hex-3-yl]-N ⁴ -(2,2-dimethylpropyl)pyrimidine-2,4-diamine	277
127		N-(2,2-Dimethylpropyl)-6-[(4aR*,7aR*)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidin-4-amine	290





Examples 128 to 132

The following compounds were prepared by a method similar to that described for example 60 and preparation 26 by reaction of the compound of preparation 12 with an appropriate amine and subsequent deprotection.









5













No.	R ¹	Name	LRMS m/z
128		6-[3-(Methylamino)azetidin-1-yl]-N ⁴ -(2-methylbutyl)pyrimidine-2,4-diamine	265




129		N ⁴ -[(1S)-1,2-Dimethylpropyl]-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine	265
130		N ⁴ -(2,5-Difluorobenzyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine	321
131		N ⁴ -(2,3-Difluorobenzyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine	321
132		N ⁴ -Butyl-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine	251

Examples 133 to 153

The following compounds were prepared by a method similar to that described for preparation 26 (solvent and temperature indicated in the table for a period between 10 and 72 hours) using the appropriate pyrimidine starting material and the appropriate amine. Deprotection (if necessary) was carried out using conditions described for example 60.

No.	Structure	Name	Cond.	Prep.	Depr.	LRMS m/z
133		6-(1,4-Diazepan-1-yl)-N ⁴ -isobutylpyrimidine-2,4-diamine	Neat / 120°C	34	Y	265
134		6-[(3R)-3-(Methylamino)pyrrolidin-1-yl]-N ⁴ -(2-methylcyclopropyl)pyrimidine-2,4-diamine	DMSO / 130°C	35	Y	263
135		N ⁴ -Isobutyl-6-(4-methyl-1,4-diazepan-1-yl)pyrimidine-2,4-diamine	Neat / 120°C	36	N	279
136		N ⁴ -(Cyclopropylmethyl)-6-(3-pyrrolidin-1-ylazetidin-1-yl)pyrimidine-2,4-diamine	NMP / 150°C	37	N	289
137		N ⁴ -Isopropyl-6-[(3aR*,7aS*)-octahydro-5H-pyrrolo[3,2-c]pyridin-5-yl]pyrimidine-2,4-diamine	DMSO / 120°C	38	Y	277
138		N ⁴ -Bicyclo[1.1.1]pent-1-yl-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine	DMSO / 120°C	39	Y	275

139		6-(4-Aminopiperidin-1-yl)-N ⁴ -ethylpyrimidine-2,4-diamine	Neat / 120°C	40	Y	237
140		6-[3-Methyl-3-(methylamino)azetidin-1-yl]-N ⁴ -propylpyrimidine-2,4-diamine	DMSO / 120°C	41	Y	251
141		N ⁴ -(2,2-Dimethylpropyl)-6-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)pyrimidine-2,4-diamine	NMP / 145°C	42	N	305
142		N ⁴ -(2,2-Dimethylpropyl)-6-(3-pyrrolidin-1-ylazetidin-1-yl)pyrimidine-2,4-diamine	NMP / 150°C	19	N	305
143		N ⁴ -(2,2-Dimethylpropyl)-N ⁶ -[2-(methylamino)ethyl]pyrimidine-2,4,6-triamine	Neat / 120°C	19	Y	253
144		N ⁴ -[2-(Dimethylamino)ethyl]-N ⁶ -(2,2-dimethylpropyl)pyrimidine-2,4,6-triamine	Neat / 120°C	19	N	267
145		N ⁴ -(2,2-Dimethylpropyl)-6-[3-(isopropylamino)azetidin-1-yl]pyrimidine-2,4-diamine	NMP / 150°C	19	Y	293
146		6-[(3R)-3-(Methylamino)pyrrolidin-1-yl]-N-[(1R)-1-methylpropyl]pyrimidin-4-amine	Neat / 120°C	10	Y	250
147		N-Butyl-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine	Neat / 120°C	10	Y	250
148		N ⁴ -(<i>tert</i> -Butyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine	NMP / 160°C	43	Y	265
149		6-[(3R)-3-(Methylamino)pyrrolidin-1-yl]-N ⁴ -(1-methylcyclopropyl)pyrimidine-2,4-diamine	DMSO / 130°C	44	Y	263
150		N ⁴ -(<i>tert</i> -Butyl)-6-[(4aS*,7aS*)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine	NMP / 170°C	43	Y	291

151		6-[(3R)-3-(Methylamino)pyrrolidin-1-yl]-N ⁴ -[(1S)-1-methylpropyl]pyrimidine-2,4-diamine	DMSO / 120°C	15	Y	265
152		6-[(3R)-3-(Methylamino)pyrrolidin-1-yl]-N ⁴ -[(1R)-1-methylpropyl]pyrimidine-2,4-diamine	DMSO / 120°C	15	Y	265
153		N-(sec-Butyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine	Neat / 120°C	1	Y	235

The following compounds were prepared by similar method to those used to prepare the compounds above, using the appropriate pyrimidine starting material and the appropriate amine:

Example

Name

- 154 N⁴-(Cyclopropylmethyl)-6-piperazin-1-ylpyrimidine-2,4-diamine
- 155 N⁴-(4-Fluorobenzyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine
- 156 N⁴-(2,2-Dimethylpropyl)-6-piperazin-1-ylpyrimidine-2,4-diamine
- 157 N⁴-(2,4-Difluorobenzyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine
- 158 6-[3-(Methylamino)azetidin-1-yl]-N⁴-(1-methylbutyl)pyrimidine-2,4-diamine
- 159 N⁴-(2,2-Dimethylpropyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine hydrochloride
- 160 N⁴-[(1R)-1,2-Dimethylpropyl]-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine
- 161 6-[3-(Methylamino)azetidin-1-yl]-N⁴-[(1S)-1-methylpropyl]pyrimidine-2,4-diamine
- 162 N⁴-(2,2-Dimethylpropyl)-6-[(3aR*,7aS*)-octahydro-5H-pyrrolo[3,2-c]pyridin-5-yl]pyrimidine-2,4-diamine
- 163 6-Piperazin-1-yl-N⁴-propylpyrimidine-2,4-diamine
- 164 N⁴-Ethyl-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine
- 165 N⁴-(Cyclopropylmethyl)-6-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine
- 166 N⁴-(2,2-Dimethylpropyl)-6-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine
- 167 N⁴-(Cyclopropylmethyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine

- 168 N⁴-(*tert*-Butyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine
- 169 N⁴-Isopropyl-6-[(4a*S*,7a*S*)-octahydro-6H-pyrrolo[3,4-*b*]pyridin-6-yl]pyrimidine-2,4-diamine
- 170 6-(3-Aminoazetidin-1-yl)-N⁴-ethylpyrimidine-2,4-diamine
- 171 6-(3-Aminoazetidin-1-yl)-N⁴-(cyclopropylmethyl)pyrimidine-2,4-diamine
- 172 N⁴-Cyclopropyl-6-[(3a*R*^{*},7a*S*^{*})-octahydro-5H-pyrrolo[3,2-*c*]pyridin-5-yl]pyrimidine-2,4-diamine
- 173 4-[3-(Methylamino)azetidin-1-yl]-6-(4-methylpiperidin-1-yl)pyrimidin-2-amine
- 174 N⁴-(Cyclopentylmethyl)-6-[(3*R*)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine
- 175 6-(1,4-Diazepan-1-yl)-N⁴-ethylpyrimidine-2,4-diamine
- 176 N⁴-(Cyclopropylmethyl)-N⁶-[2-(dimethylamino)ethyl]pyrimidine-2,4,6-triamine
- 177 N⁴-(2,2-Dimethylpropyl)-6-[(3*S*)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine
- 178 N⁴-Cyclobutyl-6-[(4a*S*,7a*S*)-octahydro-6H-pyrrolo[3,4-*b*]pyridin-6-yl]pyrimidine-2,4-diamine
- 179 N-Cyclobutyl-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine
- 180 6-[(3*R*)-3-(Methylamino)pyrrolidin-1-yl]-N⁴-propylpyrimidine-2,4-diamine
- 181 N-Cyclobutyl-6-[(3*R*)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine
- 182 N⁴-(2-Methoxyethyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine
- 183 N-(2,2-Dimethylpropyl)-6-[(3*R*)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine
- 184 N⁴-(Cyclopropylmethyl)-6-[(3*S*)-3-methylpiperazin-1-yl]pyrimidine-2,4-diamine
- 185 N⁴-Ethyl-6-(4-methyl-1,4-diazepan-1-yl)pyrimidine-2,4-diamine
- 186 N⁴-(2,2-Dimethylpropyl)-6-[3-methyl-3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine
- 187 N⁴-Isopropyl-6-piperazin-1-ylpyrimidine-2,4-diamine
- 188 N⁴-(Cyclopropylmethyl)-6-[(3a*R*^{*},7a*S*^{*})-octahydro-5H-pyrrolo[3,2-*c*]pyridin-5-yl]pyrimidine-2,4-diamine
- 189 N-Cyclopropyl-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine
- 190 6-(3-Aminoazetidin-1-yl)-N⁴-(2,2-dimethylpropyl)pyrimidine-2,4-diamine
- 191 N⁴-(2,2-Dimethylpropyl)-6-[(1*S*,4*S*)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]pyrimidine-2,4-diamine

- 192 N-(2,2-Dimethylpropyl)-6-(3-pyrrolidin-1-ylazetidin-1-yl)pyrimidin-4-amine
- 193 N⁴-Ethyl-6-[(3aR*,7aS*)-octahydro-5H-pyrrolo[3,2-c]pyridin-5-yl]pyrimidine-2,4-diamine
- 194 N-(Cyclopropylmethyl)-N'-[2-(dimethylamino)ethyl]pyrimidine-4,6-diamine
- 195 6-[(3R)-3-Aminopyrrolidin-1-yl]-N⁴-(2-methylbutyl)pyrimidine-2,4-diamine
- 196 N⁴-(Cyclopropylmethyl)-6-[3-methyl-3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine
- 197 N⁴-Ethyl-6-(3-pyrrolidin-1-ylazetidin-1-yl)pyrimidine-2,4-diamine
- 198 N⁴-Isopropyl-6-(4-methyl-1,4-diazepan-1-yl)pyrimidine-2,4-diamine
- 199 N⁴-Cyclobutyl-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine
- 200 N⁴-Methyl-6-[(3aR*,7aS*)-octahydro-5H-pyrrolo[3,2-c]pyridin-5-yl]pyrimidine-2,4-diamine
- 201 6-(4-Aminopiperidin-1-yl)-N⁴-(2,2-dimethylpropyl)pyrimidine-2,4-diamine
- 202 N-Isopropyl-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine
- 203 N-Cyclopropyl-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine
- 204 N⁴-(Cyclopropylmethyl)-6-[(3S)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine
- 205 N⁴-Ethyl-6-[(3S)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine
- 206 6-[3-(Methylamino)azetidin-1-yl]-N-propylpyrimidin-4-amine
- 207 N⁴-(*tert*-Butyl)-6-[(3S)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine
- 208 N⁴-Methyl-6-piperazin-1-ylpyrimidine-2,4-diamine
- 209 N⁴-(2,2-Dimethylpropyl)-6-{3-[(methylamino)methyl]azetidin-1-yl}pyrimidine-2,4-diamine
- 210 N⁴-(Cyclopropylmethyl)-6-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine
- 211 N⁴-(3,3-Dimethylbutyl)-6-[(3S)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine
- 212 N⁴-(2-Aminoethyl)-N⁶-(cyclopropylmethyl)pyrimidine-2,4,6-triamine
- 213 N⁴-(2-Fluorobenzyl)-6-[(3S)-3-methylpiperazin-1-yl]pyrimidine-2,4-diamine
- 214 N⁴-Ethyl-6-piperazin-1-ylpyrimidine-2,4-diamine
- 215 6-[(3R)-3-Aminopyrrolidin-1-yl]-N⁴-(cyclopropylmethyl)pyrimidine-2,4-diamine

- 216 6-[(3R)-3-Aminopyrrolidin-1-yl]-N⁴-isobutylpyrimidine-2,4-diamine
- 217 6-[(3aR*,6aS*)-Hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-N⁴-isobutylpyrimidine-2,4-diamine
- 218 6-[(3R)-3-Aminopyrrolidin-1-yl]-N⁴-(cyclopentylmethyl)pyrimidine-2,4-diamine
- 219 6-[(3R)-3-Aminopyrrolidin-1-yl]-N⁴-propylpyrimidine-2,4-diamine
- 220 N-(2-Aminoethyl)-N'-(cyclopropylmethyl)pyrimidine-4,6-diamine
- 221 N⁴-Methyl-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine
- 222 N⁴-[(1R*,5S*,6S*)-3-Azabicyclo[3.1.0]hex-6-yl]-N⁶-(2,2-dimethylpropyl)pyrimidine-2,4,6-triamine
- 223 N⁴-(*tert*-Butyl)-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine
- 224 N-Cyclopropyl-6-(4-methyl-1,4-diazepan-1-yl)pyrimidin-4-amine
- 225 6-[(3R)-3-Aminopyrrolidin-1-yl]-N⁴-(3,3-dimethylbutyl)pyrimidine-2,4-diamine
- 226 N-(2,2-Dimethylpropyl)-6-[3-(isopropylamino)azetidin-1-yl]pyrimidin-4-amine
- 227 N⁴-(Cyclopropylmethyl)-6-[3-[(methylamino)methyl]azetidin-1-yl]pyrimidine-2,4-diamine
- 228 N⁴-(3-Fluorobenzyl)-6-[(3S)-3-methylpiperazin-1-yl]pyrimidine-2,4-diamine
- 229 6-(4-Aminopiperidin-1-yl)-N⁴-isobutylpyrimidine-2,4-diamine
- 230 N⁴-Cyclobutyl-6-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine
- 231 N⁴-Isopropyl-6-(octahydro-5H-pyrrolo[3,2-c]pyridin-5-yl)pyrimidine-2,4-diamine
- 232 6-(3-Aminoazetidin-1-yl)-N⁴-propylpyrimidine-2,4-diamine
- 233 N⁴-(3,4-Difluorobenzyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine
- 234 6-(4-Aminopiperidin-1-yl)-N⁴-isopropylpyrimidine-2,4-diamine
- 235 6-[(3R)-3-(Methylamino)pyrrolidin-1-yl]-N⁴-(3,3,3-trifluoropropyl)pyrimidine-2,4-diamine
- 236 4-(3,3-Difluoroazetidin-1-yl)-6-[3-(methylamino)azetidin-1-yl]pyrimidin-2-amine
- 237 N⁴-(2-Fluorobenzyl)-6-[(3R)-3-methylpiperazin-1-yl]pyrimidine-2,4-diamine
- 238 6-[(3aR*,6aS*)-Hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-N⁴-isopropylpyrimidine-2,4-diamine
- 239 N-(2,2-Dimethylpropyl)-6-(4-methyl-1,4-diazepan-1-yl)pyrimidin-4-amine

- 240 N⁴-(4-Fluorobenzyl)-6-[(3S)-3-methylpiperazin-1-yl]pyrimidine-2,4-diamine
- 241 N⁴-Isopropyl-6-[(3aR*,6aS*)-5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]pyrimidine-2,4-diamine
- 242 4-[3-(Methylamino)azetidin-1-yl]-6-[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-amine
- 243 N⁴-(Cyclobutylmethyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine
- 244 N-(3,3-Dimethylbutyl)-6-(3-pyrrolidin-1-ylazetidin-1-yl)pyrimidin-4-amine
- 245 N⁴-(2,5-Difluorobenzyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine
- 246 6-(3-Amino-3-methylpyrrolidin-1-yl)-N⁴-(cyclopropylmethyl)pyrimidine-2,4-diamine
- 247 N⁴-(4-Fluorobenzyl)-6-[(3R)-3-methylpiperazin-1-yl]pyrimidine-2,4-diamine
- 248 N⁴-Methyl-6-[3-methyl-3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine
- 249 N⁴-(3-Fluorobenzyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine
- 250 N⁴-(2,2-Dimethylpropyl)-6-[3-(methylamino)piperidin-1-yl]pyrimidine-2,4-diamine
- 251 N⁴-Benzyl-6-[(3S)-3-methylpiperazin-1-yl]pyrimidine-2,4-diamine
- 252 N-Cyclopropyl-6-[(3S)-3-methylpiperazin-1-yl]pyrimidin-4-amine
- 253 N⁴-(2-Fluorobenzyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine
- 254 N⁴-Benzyl-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine
- 255 6-[(3R)-3-Aminopyrrolidin-1-yl]-N⁴-(2,3-difluorobenzyl)pyrimidine-2,4-diamine
- 256 N⁴-Cyclopropyl-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine
- 257 N⁴-Ethyl-6-[3-methyl-3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine
- 258 6-[(3S)-3-Methylpiperazin-1-yl]-N-propylpyrimidin-4-amine
- 259 N⁴-Benzyl-6-[(3R)-3-methylpiperazin-1-yl]pyrimidine-2,4-diamine
- 260 6-(4-Cyclohexylpiperazin-1-yl)-N-(2,2-dimethylpropyl)pyrimidin-4-amine
- 261 N-Isopropyl-6-[3-methyl-3-(methylamino)azetidin-1-yl]pyrimidin-4-amine
- 262 N-Methyl-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine
- 263 4-[3-(Methylamino)azetidin-1-yl]-6-[(3R)-3-methylmorpholin-4-yl]pyrimidin-2-amine

- 264 6-(3-Amino-3-methylpyrrolidin-1-yl)-N⁴-propylpyrimidine-2,4-diamine
- 265 6-(3-Amino-3-methylpyrrolidin-1-yl)-N⁴-ethylpyrimidine-2,4-diamine
- 266 6-(4-Aminopiperidin-1-yl)-N⁴-propylpyrimidine-2,4-diamine
- 267 N⁴-(3-Fluorobenzyl)-6-[(3R)-3-methylpiperazin-1-yl]pyrimidine-2,4-diamine
- 268 4-[3-(Methylamino)azetidin-1-yl]-6-morpholin-4-ylpyrimidin-2-amine
- 269 6-(4-Aminopiperidin-1-yl)-N⁴-cyclopropylpyrimidine-2,4-diamine
- 270 N-(3,3-Dimethylbutyl)-6-(4-ethylpiperazin-1-yl)pyrimidin-4-amine
- 271 N⁴-(2,6-Difluorobenzyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine
- 272 N⁴-(2,3-Difluorobenzyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine
- 273 N⁴-(3,5-Difluorobenzyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine
- 274 (5-[[[(3S)-3-[[6-[(3,3-Dimethylbutyl)amino]pyrimidin-4-yl]amino]pyrrolidin-1-yl]methyl]-2-furyl])methanol
- 275 4-(3,3-Difluoroazetidin-1-yl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-2-amine
- 276 N,N'-Bis(cyclopropylmethyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine
- 277 N⁴-(3,4-Difluorobenzyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine
- 278 N⁴-Isobutyl-6-[3-(methylamino)piperidin-1-yl]pyrimidine-2,4-diamine
- 279 N'-(3,3-Dimethylbutyl)-N-methyl-N-(1-methylpiperidin-4-yl)pyrimidine-4,6-diamine
- 280 6-(1,4-Diazepan-1-yl)-N-(3,3-dimethylbutyl)pyrimidin-4-amine
- 281 N-Benzyl-N'-[(3S)-pyrrolidin-3-yl]pyrimidine-4,6-diamine
- 282 4-[(3R)-3-(Methylamino)pyrrolidin-1-yl]-6-morpholin-4-ylpyrimidin-2-amine
- 283 6-(4-Aminopiperidin-1-yl)-N⁴-(cyclopropylmethyl)pyrimidine-2,4-diamine
- 284 6-(4-Aminopiperidin-1-yl)-N⁴-methylpyrimidine-2,4-diamine
- 285 N-(Cyclopropylmethyl)-6-piperazin-1-ylpyrimidin-4-amine
- 286 N⁴-Isopropyl-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine
- 287 N⁴-(2,2-Dimethylpropyl)-6-(3-morpholin-4-ylazetidin-1-yl)pyrimidine-2,4-diamine

- 288 N-(3,3-Dimethylbutyl)-N'-(1-methylpiperidin-3-yl)pyrimidine-4,6-diamine
- 289 N-[(3S)-1-Benzylpyrrolidin-3-yl]-N'-(3,3-dimethylbutyl)pyrimidine-4,6-diamine
- 290 N-[(3S)-Pyrrolidin-3-yl]-N'-[(2S)-tetrahydrofuran-2-ylmethyl]pyrimidine-4,6-diamine
- 291 N-(Cyclopropylmethyl)-5-methyl-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine
- 292 6-(3-Aminopyrrolidin-1-yl)-N-(3,3-dimethylbutyl)pyrimidin-4-amine
- 293 4-[6-(4-Methylpiperazin-1-yl)pyrimidin-4-yl]morpholine
- 294 N⁴-(Cyclopropylmethyl)-6-[3-(methylamino)piperidin-1-yl]pyrimidine-2,4-diamine
- 295 4-[3-(Methylamino)azetidin-1-yl]-6-piperidin-1-ylpyrimidin-2-amine
- 296 N-(3,3-Dimethylbutyl)-N'-[(3S)-1-methylpyrrolidin-3-yl]pyrimidine-4,6-diamine
- 297 (1S,5R)-3-{6-[(2,2-Dimethylpropyl)amino]pyrimidin-4-yl}-3-azabicyclo[3.1.0]hexan-1-amine
- 298 N⁴-(3,3-Dimethylbutyl)-6-[3-methyl-3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine
- 299 N-(3,3-Dimethylbutyl)-6-[4-[(1-methyl-1H-imidazol-2-yl)methyl]piperazin-1-yl]pyrimidin-4-amine
- 300 (1R*,5S*,6s*)-3-{6-[(3,3-Dimethylbutyl)amino]pyrimidin-4-yl}-N,N-dimethyl-3-azabicyclo[3.1.0]hexan-6-amine
- 301 N-(3,3-Dimethylbutyl)-6-(4-pyrrolidin-1-ylpiperidin-1-yl)pyrimidin-4-amine
- 302 6-[3-(Diethylamino)pyrrolidin-1-yl]-N-(2,2-dimethylpropyl)pyrimidin-4-amine
- 303 6-(4-Azetidin-3-ylpiperazin-1-yl)-N-(2,2-dimethylpropyl)pyrimidin-4-amine
- 304 (1S*,5R*)-3-{6-[(Cyclopropylmethyl)amino]pyrimidin-4-yl}-3-azabicyclo[3.1.0]hexan-1-amine
- 305 6-(4-Cyclohexylpiperazin-1-yl)-N-(cyclopropylmethyl)pyrimidin-4-amine
- 306 N'-(Cyclopropylmethyl)-N-[2-(diethylamino)ethyl]-N-methylpyrimidine-4,6-diamine
- 307 2-{4-[6-[(3,3-Dimethylbutyl)amino]pyrimidin-4-yl]piperazin-1-yl}ethanol
- 308 6-(4-Azetidin-3-ylpiperazin-1-yl)-N-(cyclopropylmethyl)pyrimidin-4-amine
- 309 N⁴-(3,3-Dimethylbutyl)-6-[(1R,5S,6s)-6-(methylamino)-3-azabicyclo[3.1.0]hex-3-yl]pyrimidine-2,4-diamine
- 310 N⁴-(Cyclopropylmethyl)-6-[(3R)-3-methylpiperazin-1-yl]pyrimidine-2,4-diamine
- 311 6-[(3R)-3-Aminopyrrolidin-1-yl]-N⁴-(2,5-difluorobenzyl)pyrimidine-2,4-diamine

- 312 N-(3,3-Dimethylbutyl)-6-(3-morpholin-4-ylazetidin-1-yl)pyrimidin-4-amine
- 313 6-[(3R)-3-Methylpiperazin-1-yl]-N-propylpyrimidin-4-amine
- 314 N-Cyclopropyl-6-(1,4-diazepan-1-yl)pyrimidin-4-amine
- 315 N-(2-Phenylethyl)-N'-[(3S)-pyrrolidin-3-yl]pyrimidine-4,6-diamine
- 316 N⁴-(3,5-Difluorobenzyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine
- 317 N⁴-(2,6-Difluorobenzyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine
- 318 N⁴-(2,2-Dimethylpropyl)-6-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine
- 319 N-[(3S)-Pyrrolidin-3-yl]-N'-[(2R)-tetrahydrofuran-2-ylmethyl]pyrimidine-4,6-diamine
- 320 6-(3-Amino-3-methylpyrrolidin-1-yl)-N⁴-methylpyrimidine-2,4-diamine
- 321 N⁴-Methyl-6-[3-(methylamino)piperidin-1-yl]pyrimidine-2,4-diamine
- 322 N⁴-(Cyclopropylmethyl)-6-(3-morpholin-4-ylazetidin-1-yl)pyrimidine-2,4-diamine
- 323 6-[3-(Methylamino)piperidin-1-yl]-N⁴-propylpyrimidine-2,4-diamine
- 324 N⁴-Ethyl-6-[3-(methylamino)piperidin-1-yl]pyrimidine-2,4-diamine
- 325 N⁴-(2,4-Difluorobenzyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine
- 326 N-(2,2-Dimethylpropyl)-5-methyl-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine
- 327 6-[(3'S)-1,3'-Bipyrrolidin-1'-yl]-N⁴-(2,2-dimethylpropyl)pyrimidine-2,4-diamine
- 328 N-(3,3-Dimethylbutyl)-6-[(4aR*,7aR*)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidin-4-amine
- 329 N-(3-Methylbutyl)-N'-[(3R)-pyrrolidin-3-yl]pyrimidine-4,6-diamine
- 330 N⁴-(3,3-Dimethylbutyl)-N²,N²-dimethyl-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine
- 331 N-isoPropyl-5-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-amine
- 332 6-[(3'S)-1,3'-Bipyrrolidin-1'-yl]-N⁴-(3,3-dimethylbutyl)pyrimidine-2,4-diamine
- 333 6-[(1R*,5S*,6s*)-6-Amino-3-azabicyclo[3.1.0]hex-3-yl]-N⁴-(3,3-dimethylbutyl)pyrimidine-2,4-diamine
- 334 N-(Cyclopropylmethyl)-N-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-amine
- 335 N-(2-Methoxyethyl)-N'-[(3R)-pyrrolidin-3-yl]pyrimidine-4,6-diamine

- 336 N-Methyl-1-(6-pyrrolidin-1-ylpyrimidin-4-yl)azetidin-3-amine
- 337 N-Benzyl-N'-[(3R)-pyrrolidin-3-yl]pyrimidine-4,6-diamine
- 338 N⁴-[(3S)-1-Benzylpyrrolidin-3-yl]-N⁶-(3,3-dimethylbutyl)pyrimidine-2,4,6-triamine
- 339 N⁴-(3,3-Dimethylbutyl)-N²-methyl-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine
- 340 6-(4-Aminopiperidin-1-yl)-N-(3,3-dimethylbutyl)pyrimidin-4-amine
- 341 N-[(3R)-Pyrrolidin-3-yl]-N'-[(2S)-tetrahydrofuran-2-ylmethyl]pyrimidine-4,6-diamine
- 342 6-[(3'S)-1,3'-Bipyrrolidin-1'-yl]-N-(3,3-dimethylbutyl)pyrimidin-4-amine
- 343 N-(3,3-Dimethylbutyl)-N'-(1-methylpiperidin-4-yl)pyrimidine-4,6-diamine
- 344 N-(2-Methoxyethyl)-N'-[(3S)-pyrrolidin-3-yl]pyrimidine-4,6-diamine
- 345 N-[(3R)-Pyrrolidin-3-yl]-N'-[(2R)-tetrahydrofuran-2-ylmethyl]pyrimidine-4,6-diamine
- 346 N-(2-Phenylethyl)-N'-[(3R)-pyrrolidin-3-yl]pyrimidine-4,6-diamine
- 347 N-(Cyclopropylmethyl)-N'-[2-(methylamino)ethyl]pyrimidine-4,6-diamine
- 348 N-[(3R)-1-Benzylpyrrolidin-3-yl]-N'-(3,3-dimethylbutyl)pyrimidine-4,6-diamine
- 349 (5-[[[(3R)-3-[(6-[(3,3-Dimethylbutyl)amino]pyrimidin-4-yl)amino]pyrrolidin-1-yl]methyl]-2-furyl]methanol
- 350 N-(2,3-Dihydro-1H-inden-2-yl)-N'-[(3R)-pyrrolidin-3-yl]pyrimidine-4,6-diamine
- 351 6-(3,4-Dihydroisoquinolin-2(1H)-yl)-N-[(3R)-pyrrolidin-3-yl]pyrimidin-4-amine
- 352 N⁴-(3-Fluorobenzyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine
- 353 N-(2,2-Dimethylpropyl)-6-[(1R,5S)-1,2,4,5-tetrahydro-3H-1,5-epimino-3-benzazepin-3-yl]pyrimidin-4-amine
- 354 N⁴-Cyclobutyl-6-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine
- 355 N⁴-(Cyclopropylmethyl)-6-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine
- 356 N⁴-(*tert*-Butyl)-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine
- 357 N⁴-(*tert*-Butyl)-6-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine
- 358 N⁴-(2,2-Dimethylpropyl)-6-[(1R*,5S*,6S*)-6-(methylamino)-3-azabicyclo[3.1.0]hex-3-yl]pyrimidine-2,4-diamine
- 359 N⁴-Cyclopropyl-6-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine

- 360 2-((2-Amino-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-yl)amino)ethanol
- 361 6-(1,4-Diazepan-1-yl)-N⁴-isopropylpyrimidine-2,4-diamine
- 362 6-[(1R,4R)-2,5-Diazabicyclo[2.2.1]hept-2-yl]-N⁴-(2,2-dimethylpropyl)pyrimidine-2,4-diamine
- 363 6-[(3R)-3-Aminopyrrolidin-1-yl]-N⁴-(2,2-dimethylpropyl)pyrimidine-2,4-diamine
- 364 4-[(3R)-3-(Methylamino)pyrrolidin-1-yl]-6-(2-methyl-1H-imidazol-1-yl)pyrimidin-2-amine
- 365 6-[3-(Methylamino)azetidin-1-yl]-N⁴-[(1R)-1-methylpropyl]pyrimidine-2,4-diamine
- 366 6-[(3R)-3-Aminopyrrolidin-1-yl]-N⁴-ethylpyrimidine-2,4-diamine
- 367 6-[(3R)-3-Aminopyrrolidin-1-yl]-N⁴-(3,3,3-trifluoropropyl)pyrimidine-2,4-diamine
- 368 6-[(3R)-3-(Methylamino)pyrrolidin-1-yl]-N-[(1S)-1-methylpropyl]pyrimidin-4-amine
- 369 6-[3-(Methylamino)azetidin-1-yl]-N-[(1R)-1-methylpropyl]pyrimidin-4-amine
- 370 6-[(3R)-3-(Methylamino)pyrrolidin-1-yl]-N-propylpyrimidin-4-amine
- 371 6-(3-Aminoazetidin-1-yl)-N-(2,2-dimethylpropyl)pyrimidin-4-amine
- 372 N⁴-(Cyclopropylmethyl)-5-methyl-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine
- 373 N⁴-(Cyclopropylmethyl)-6-(2,8-diazaspiro[4.5]dec-2-yl)pyrimidine-2,4-diamine
- 374 6-(2,8-Diazaspiro[4.5]dec-2-yl)-N⁴-isobutylpyrimidine-2,4-diamine
- 375 N⁴-(Cyclopropylmethyl)-6-(2,7-diazaspiro[4.4]non-2-yl)pyrimidine-2,4-diamine
- 376 6-(2,7-Diazaspiro[4.4]non-2-yl)-N⁴-isobutylpyrimidine-2,4-diamine

Biology

H₄ Binding

- Cell pellets from CHO cells expressing the histamine H₄ receptor were homogenised in ice-cold 50mM
- 5 Tris-HCl/0.5mM CaCl₂ buffer containing a protease inhibitor cocktail (Roche®, United Kingdom) using a ground glass homogeniser. Homogenates were centrifuged at 48000g for 30min at 4°C. The membrane pellet was resuspended in fresh buffer and the centrifugation step was repeated as described above. The membrane pellet was resuspended in 50mM Tris-HCl in the same volume as the original cell pellet. Aliquots of membrane preparations were stored at -80°C and were used for [³H]-Histamine binding
- 10 experiments.

Method 1

Cell membranes (20-35µg/well) were incubated for 90 minutes shaking at room temperature with 3nM [2,5-³H]Histamine dihydrochloride (30-60Ci/mmol) in 50mM Tris-HCl (pH 7.4), with or without competing H₄ ligands. The reaction was terminated by rapid filtration through 0.5% polyethylenimine-soaked Unifilter GF/B plates (Packard) followed by three washes with 1ml ice-cold 50mM Tris-HCl. Filters were dried for 45min at 45°C and bound radiolabel was determined using scintillation counting techniques. Non-specific binding was defined with 10µM JNJ7777120. For competition binding studies, K_i values were calculated from the IC₅₀ value based on an experimentally determined ligand K_d of 5.2nM and a ligand concentration of 5nM according to the Cheng-Prusoff equation where; $K_i = (IC_{50}) / (1 + ([L]/K_d))$.

Method 2

Cell membranes (15µg/well) were pre-incubated for 120min shaking at 4°C with Ysi WGA beads (250µg/well) in 50mM Tris-HCl (pH 7.4) followed by centrifugation at 1500rpm for 5minutes and resuspension in 50mM Tris-HCl (pH 7.4). The membrane/bead mixture (15µg membrane / 250µg beads well) was incubated for 90minutes shaking at room temperature with 6.5nM [2,5-³H] Histamine dihydrochloride (30-60Ci/mmol) in 50mM Tris-HCl (pH 7.4), with or without competing H₄ ligands. Non-specific binding was defined with 10µM JNJ7777120. Bound radiolabel was determined using scintillation counting techniques after 90 minutes. For competition binding studies, K_i values were calculated from the IC₅₀ value based on an experimentally determined ligand K_d of 5.2nM and a ligand concentration of 5nM according to the Cheng-Prusoff equation where; $K_i = (IC_{50}) / (1 + ([L]/K_d))$.

The compounds of the Examples have been tested in the H₄ binding assay described above using either method 1 or method 2. Preferred examples have a K_i value of less than 1 µM in the H₄ binding assay. Most preferred examples have a K_i value of less than 500 nM in the H₄ binding assay (method 2). The specific K_i values for the Example compounds that have been tested in method 1 and method 2 are given in the table below:

Example	Method 2 (K _i (nM))	Method 1 (K _i (nM))
1	335	82,3
2	NT	485
3	NT	220
4	NT	374
5	NT	263
6	NT	502
7	NT	939
8	NT	593
9	19,3	2,7
10	4,11	2,85
11	31,6	10,6
12	52,4	NT
13	51,8	NT
14	23,3	13,6

Example	Method 2 (K _i (nM))	Method 1 (K _i (nM))
15	19,2	NT
16	1740	NT
17	483	NT
18	387	NT
19	132	NT
20	58,1	30,5
21	722	NT
22	59,3	58,9
23	824	NT
24	30,8	NT
25	154	NT
26	30	NT
27	22,4	NT
28	21,3	NT
29	82,9	NT

Example	Method 2 (Ki (nM))	Method 1 (Ki (nM))
30	19,3	3,06
31	21,1	NT
32	20,9	NT
33	84,1	NT
34	452	NT
35	662	NT
36	1620	NT
37	181	NT
38	128	NT
39	88,9	NT
41	202	NT
40	192	NT
42	433	NT
43	236	NT
44	20,5	NT
45	420	NT
46	40,1	NT
47	256	NT
48	49,7	NT
49	29,9	10,7
50	279	NT
51	161	NT
52	99,7	NT
53	1940	NT
54	414	NT
55	28,9	NT
56	1590	NT
57	20,3	NT
58	301	NT
59	59,2	37,7
60	28,8	3,57
61	1,33	1,66
62	14,1	8,94
63	12,2	1,95
64	4,43	4,63
65	19,8	17,5
66	61,1	NT
67	1,6	0,278
68	6,26	0,979
69	9,38	NT
70	2,14	3,79
71	14	1,29
72	11,9	NT
73	NT	0,88
74	16,8	0,58
75	NT	1,07
76	125	NT
77	255	NT
78	3,66	NT
79	11,2	NT
80	103	NT

Example	Method 2 (Ki (nM))	Method 1 (Ki (nM))
81	12,1	NT
82	9,68	NT
83	62,3	NT
84	21,7	NT
85	156	NT
86	142	NT
87	17,4	NT
88	35,8	NT
89	1,93	NT
90	6,42	NT
91	386	NT
92	1350	NT
93	256	NT
94	61,1	NT
95	9,11	NT
96	3,77	NT
97	43,7	NT
98	56,2	NT
99	38,1	23,6
100	NT	40,2
101	NT	463
102	NT	57,3
103	NT	87,9
104	NT	118
105	NT	68,8
106	NT	66,1
107	NT	271
108	8,42	NT
109	42,7	NT
110	829	NT
111	1800	201
112	635	NT
113	1480	NT
114	1030	NT
115	494	NT
116	426	NT
117	1620	NT
118	1090	NT
119	7,8	3,44
120	11,2	4,89
121	6,64	2,18
122	8,65	3,65
123	103	NT
124	537	NT
125	223	NT
126	611	NT
127	65,8	NT
128	NT	0,805
129	NT	3,78
130	NT	9,69
131	NT	17,8

Example	Method 2 (Ki (nM))	Method 1 (Ki (nM))
132	NT	0,791
133	NT	0,653
134	NT	4,15
135	NT	1,13
136	NT	7,21
137	NT	8,25
138	NT	5,8
139	NT	12,1
140	NT	12,1
141	4,97	
142	NT	3,04
143	NT	72,4
144	NT	16,8
145	NT	14,3
146	NT	13,7
147	NT	17,3
148	NT	4,89
149	NT	5,2
150	NT	11,8
151	NT	12,4
152	NT	16,9
153	NT	11,5
154	NT	1,71
155	NT	1,78
156	NT	2,44
157	NT	2,49
158	NT	2,59
159	NT	2,62
160	NT	2,65
161	NT	2,75
162	NT	2,91
163	NT	3,78
164	24,5	3,82
165	NT	3,83
166	NT	3,99
167	NT	6,3
168	NT	6,5
169	NT	6,77
170	NT	8,55
171	NT	9,21
172	NT	9,3
173	NT	10,1
174	NT	10,6
175	NT	12,3
176	NT	15,1
177	NT	16
178	NT	16,1
179	NT	16,5
180	NT	17,4
181	NT	17,6
182	NT	19,8

Example	Method 2 (Ki (nM))	Method 1 (Ki (nM))
183	NT	20
184	NT	20,4
185	NT	20,5
186	NT	22,2
187	NT	22,4
188	NT	25,5
189	NT	25,8
190	NT	27,7
191	NT	28,2
192	NT	28,7
193	NT	31
194	NT	32,4
195	NT	32,6
196	NT	33,1
197	NT	33,2
198	NT	33,6
199	NT	33,9
200	NT	34
201	NT	35
202	NT	36,5
203	NT	37,9
204	NT	39
205	NT	39,3
206	NT	39,9
207	NT	43,3
208	NT	45,1
209	NT	46,4
210	NT	48,9
211	NT	49,3
212	NT	50
213	NT	52,9
214	NT	54,4
215	NT	57,3
216	NT	70,6
217	NT	80,6
218	NT	80,7
219	NT	82,3
220	NT	88
221	NT	90,3
222	NT	95,2
223	NT	13% at 10 μ M
224	NT	101
225	NT	102
226	NT	113
227	NT	115
228	NT	117
229	NT	127
230	NT	127
231	NT	131
232	NT	13,88
233	NT	30,4

Example	Method 2 (Ki (nM))	Method 1 (Ki (nM))
234	NT	177
235	NT	198
236	NT	205
237	NT	211
238	NT	222
239	NT	235
240	NT	238
241	NT	45% at 1 μ M
242	NT	258
243	NT	266
244	NT	297
245	NT	298
246	NT	301
247	NT	312
248	NT	329
249	NT	343
250	NT	353
251	NT	355
252	NT	370
253	NT	380
254	NT	380
255	NT	452
256	NT	501
257	NT	100% at 10 μ M
258	NT	509
259	NT	577
260	NT	100% at 10 μ M
261	NT	617
262	NT	623
263	NT	626
264	NT	704
265	NT	705
266	NT	708
267	NT	715
268	NT	16% at 10 μ M
269	NT	839
270	>16200	839
271	NT	870
272	NT	901
273	NT	950
274	NT	1070
275	NT	1160
276	NT	14% at 3.16 μ M
277	NT	1230
278	NT	1260
279	>9130	1370
280	NT	1430
281	NT	1550
282	NT	1660
283	NT	1700
284	NT	1720

Example	Method 2 (Ki (nM))	Method 1 (Ki (nM))
285	NT	1800
286	NT	1940
287	NT	2000
288	NT	2400
289	NT	44% at 10 μ M
290	NT	24% at 10 μ M
291	NT	No activity at top dose (6.3 μ M)
292	NT	2590
293	NT	3040
294	NT	91% at 20 μ M
295	NT	3180
296	NT	3300
297	NT	30% at 10 μ M
298	NT	No activity at top dose (10 μ M)
299	NT	No activity at top dose (10 μ M)
300	NT	35% at 10 μ M
301	NT	No activity at top dose (10 μ M)
302	NT	20% at 10 μ M
303	NT	38% at 10 μ M
304	NT	19% at 10 μ M
305	NT	No activity at top dose (10 μ M)
306	NT	18% at 10 μ M
307	NT	24% at 10 μ M
308	NT	No activity at top dose (10 μ M)
309	NT	26% at 10 μ M
310	NT	No activity at top dose (10 μ M)
311	NT	80% at 20 μ M
312	NT	21% at 20 μ M
313	NT	70% at 20 μ M
314	NT	No activity at top dose (10 μ M)
315	NT	5190
316	NT	No activity at top dose (10 μ M)
317	NT	No activity at top dose (10 μ M)
318	NT	No activity at top dose (10 μ M)
319	NT	6010
320	NT	46% at 6.3 μ M
321	NT	15% at 20 μ M
322	NT	57% at 20 μ M
323	NT	85% at 20 μ M
324	NT	55% at 20 μ M
325	NT	43% at 20 μ M
326	NT	48% at 20 μ M
327	376	NT
328	554	NT


Example	Method 2 (Ki (nM))	Method 1 (Ki (nM))
329	1420	NT
330	1440	NT
331	2670	NT
332	2690	NT
333	3120	NT
334	5070	NT
335	5350	NT
336	6330	NT
337	7220	NT
338	7930	NT
339	9070	NT
340	50% at 40 μ M	NT
341	16300	NT
342	13% at 40 μ M	NT
343	53% at 40 μ M	NT
344	40% at 40 μ M	NT
345	49% at 40 μ M	NT
346	38400	NT
347	NT	NT
348	NT	NT
349	NT	NT
350	NT	NT
351	NT	NT
352	NT	NT
353	NT	NT

Example	Method 2 (Ki (nM))	Method 1 (Ki (nM))
354	NT	NT
355	NT	NT
356	NT	NT
357	NT	NT
358	NT	NT
359	NT	NT
360	NT	NT
361	NT	NT
362	NT	NT
363	NT	NT
364	NT	NT
365	NT	NT
366	NT	NT
367	NT	NT
368	NT	NT
369	NT	NT
370	NT	NT
371	NT	NT
372	NT	NT
373	NT	NT
374	NT	NT
375	NT	NT
376	NT	NT

NT: not tested

Claims:

1. A compound of Formula (I):



5

or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof, wherein:

R¹ is C₁₋₈alkyl, C₃₋₇cycloalkyl-C₀₋₆alkyl- optionally substituted with methyl, alkoxyalkyl containing 3 to 8 carbon atoms, het-C₀₋₆alkyl-, CF₃-C₁₋₆alkyl-, CF₃OC₂₋₃alkyl- or C₁₋₆hydroxyalkyl;

10

R³ and R² together with the nitrogen atom to which they are bound form a 4 to 8 membered non-aromatic heterocyclic group which optionally contains one or more further heteroatoms or groups independently selected from N, O, S, S(O) and S(O)₂, wherein the heterocyclic group is optionally a bridged bicyclic group, a spiro bicyclic group or is optionally fused to a 3-, 4-, 5- or 6- membered carbocyclic group or a 4-, 5- or 6-membered heterocyclic group which contains at least one ring member independently selected from N, O, S, S(O) and S(O)₂, and wherein the ring system as a whole is optionally substituted by one or more substituents independently selected from C₁₋₆alkyl, NR⁶R⁷, (CH₂)_aC₃₋₇cycloalkyl, alkoxyalkyl containing 2 to 8 carbon atoms, (CH₂)_bhet¹, (CH₂)_cCF₃, (CH₂)_yOCF₃, (CH₂)_daryl and C₁₋₆hydroxyalkyl, provided that the ring system as a whole contains at least two nitrogen atoms or contains one nitrogen atom and is substituted by a group which contains at least one nitrogen atom;

15

R⁴ is H;

R⁵ is H or NH₂;

25

R⁶ and R⁷ are each independently selected from H, C₁₋₆alkyl and (CH₂)_jC₃₋₇cycloalkyl; or R⁶ and R⁷, together with the nitrogen atom to which they are bound, form a 4, 5 or 6 membered heterocyclic group;

R⁸ is H;

R¹³ and R¹⁴ are each independently selected from H, C₁₋₆alkyl and (CH₂)_mC₃₋₇cycloalkyl;

30

or R¹³ and R¹⁴, together with the nitrogen atom to which they are bound, form a 4, 5 or 6 membered heterocyclic group;

a, b, c, d, j and m are each independently selected from 0, 1, 2 and 3;

y is selected from 1, 2 and 3


- aryl is phenyl, naphthyl, anthracyl or phenanthryl, each optionally substituted by one or more groups independently selected from C₁₋₈alkyl, C₁₋₈alkoxy, OH, halo, CF₃, CHF₂, OCF₃, OCHF₂, SCF₃, hydroxy-C₁₋₆alkyl, C₁₋₄alkoxy-C₁₋₆alkyl, C₁₋₄alkyl-S-C₁₋₄alkyl, aryl¹, het¹, Oaryl¹, Ohet¹, Saryl¹, Shet¹, CF₂CF₃, CH₂CF₃, CF₂CH₃, C(O)NR¹³R¹⁴,
- 5 C₃₋₈cycloalkyl, C₃₋₇cycloalkyl-C₁₋₄alkyl, C₃₋₇cycloalkyl-C₁₋₄alkoxy, C₃₋₇cycloalkyl-O-C₁₋₄alkyl, C₃₋₇cycloalkyl-C₁₋₄alkoxy-C₁₋₄alkyl, OC₃₋₇cycloalkyl and SC₃₋₇cycloalkyl, wherein the aryl¹ and het¹ groups are optionally substituted by at least one group selected from C₁₋₆alkyl, C₃₋₇cycloalkyl, C₁₋₆alkoxy, OC₃₋₇cycloalkyl, halo, CN, OH, CF₃, CHF₂, OCF₃, OCHF₂, hydroxyC₁₋₆alkyl, C₁₋₄alkoxy-C₁₋₄alkyl, SC₁₋₆alkyl and
- 10 SCF₃;
- het is 4 to 8 membered non-aromatic heterocyclic group which contains at least one heteroatom or group independently selected from N, O, S, S(O) and S(O)₂, wherein the heterocyclic group is optionally a bridged bicyclic group or is optionally fused to a 3-, 4-, 5- or 6- membered carbocyclic group or a 4-, 5- or 6-membered heterocyclic group
- 15 which contains at least one ring member independently selected from N, O, S, S(O) and S(O)₂, and wherein the ring system as a whole is optionally substituted by one or more substituents independently selected from C₁₋₆alkyl, NR⁶R⁷, (CH₂)_aC₃₋₇cycloalkyl, alkoxyalkyl containing 2 to 8 carbon atoms, (CH₂)_bhet¹, (CH₂)_cCF₃, (CH₂)_yOCF₃, (CH₂)_daryl and C₁₋₆hydroxyalkyl;
- 20 aryl¹ is phenyl, naphthyl, anthracyl or phenanthryl; and
- het¹ is an aromatic or non-aromatic 4-, 5- or 6- membered heterocycle which contains at least one N, O or S heteroatom, optionally fused to a 4-, 5- or 6- membered carbocyclic group or a second 4-, 5- or 6-membered heterocycle which contains at least one N, O or S heteroatom.
- 25
2. A compound according to claim 1, or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof, wherein R¹ is C₃₋₇cycloalkyl-C₀₋₆alkyl- optionally substituted with methyl.
- 30
3. A compound according to claim 1 or claim 2, or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof, wherein R¹ is C₃₋₅cycloalkyl-C₀₋₁alkyl- optionally substituted with methyl.
- 35
4. A compound according to claim 1, or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof, wherein R¹ is cyclopropyl, cyclopropyl-methyl or methyl-cyclopropyl.
5. A compound according to claim 1, or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof, wherein R¹ is C₁-C₆ alkyl.

6. A compound according to claim 1, or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof, wherein R^1 is ethyl, propyl, butyl, 1-methyl-propyl, 2-methyl-propyl, 2,2-dimethyl-propyl, 2-methyl-butyl, ter-butyl, 1-methyl-butyl,
 5 3-methyl-butyl, 3,3-dimethyl-butyl, 1,2-dimethyl-propyl or isopropyl.

7. A compound according to any of Claims 1 to 6, or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof, wherein R^2 and R^3 , together with the nitrogen atom to which they are bound, form a 4 to 8 membered non-aromatic
 10 heterocyclic group which optionally contains one or more further heteroatoms or groups independently selected from N, O, S, S(O) and S(O)₂, wherein the heterocyclic group is optionally a bridged bicyclic group or is optionally fused to a 3-, 4-, 5- or 6- membered carbocyclic group or a 4-, 5- or 6-membered heterocyclic group which contains at least one ring member independently selected from N, O, S, S(O) and S(O)₂, and wherein the
 15 ring system as a whole is optionally substituted by one or more substituents independently selected from C₁₋₆alkyl, NR⁶R⁷, (CH₂)_aC₃₋₇cycloalkyl, alkoxyalkyl containing 2 to 8 carbon atoms, (CH₂)_bhet¹, (CH₂)_cCF₃, (CH₂)_yOCF₃, (CH₂)_daryl and C₁₋₆hydroxyalkyl, provided that the ring system as a whole contains at least two nitrogen atoms or contains one nitrogen atom and is substituted by a group which
 20 contains at least one nitrogen atom.

8. A compound according to Claim 7, or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof, wherein R^2 and R^3 , together with the nitrogen atom to which they are bound, form a 4 to 8 membered non-aromatic heterocyclic group which
 25 optionally contains one or more further nitrogen atoms, wherein the heterocyclic group is optionally a bridged bicyclic group or is optionally fused to a 3-, 4-, 5- or 6-membered carbocyclic group or a 4-, 5- or 6-membered heterocyclic group which contains at least one nitrogen atom, and wherein the ring system as a whole is optionally substituted by one or more substituents independently selected from
 30 C₁₋₆alkyl, NR⁶R⁷, (CH₂)_aC₃₋₇cycloalkyl, alkoxyalkyl containing 2 to 8 carbon atoms, (CH₂)_bhet¹, (CH₂)_cCF₃, (CH₂)_yOCF₃, (CH₂)_daryl and C₁₋₆hydroxyalkyl, provided that the ring system as a whole contains at least two nitrogen atoms or contains one nitrogen atom and is substituted by a group which contains at least one nitrogen atom.

35 9. A compound according to any of Claims 1 to 8, or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof, wherein R^2 and R^3 , together with the nitrogen atom to which they are bound, form a group selected from the following ring systems:



wherein the ring system as a whole may be substituted by one or more C_{1-6} alkyl or $(CH_2)_3C_{3-7}$ cycloalkyl groups.

- 5 10. A compound according to Claim 9, or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof, wherein R^6 and R^7 are independently selected from H or CH_3 .

11. A compound according to claim 1, or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof, said compound being selected from
- 10 N^4 -Isobutyl-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine,
 N^4 -(2,2-Dimethylpropyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine

- N-Isobutyl-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine,
 N-(Cyclopropylmethyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine,
 N⁴-(2,2-Dimethylpropyl)-6-[(4aR*,7aR*)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-
 pyrimidine-2,4-diamine,
 5 N⁴-Cyclopropyl-6-[(4aR*,7aR*)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-
 2,4-diamine,
 N⁴-Cyclobutyl-6-[(4aR*,7aR*)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-
 2,4-diamine,
 N⁴-(2,2-Dimethylpropyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine,
 10 6-(3-Methylamino-azetidin-1-yl)-N⁴-(3,3,3-trifluoro-propyl)-pyrimidine-2,4-diamine,
 N⁴-Cyclopropylmethyl-6-(3-methylamino-azetidin-1-yl)-pyrimidine-2,4-diamine,
 N⁴-(3,3-Dimethyl-butyl)-6-(3-methylamino-azetidin-1-yl)-pyrimidine-2,4-diamine,
 N⁴-Cyclopentylmethyl-6-(3-methylamino-azetidin-1-yl)-pyrimidine-2,4-diamine,
 N⁴-Isobutyl-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine,
 15 6-[3-(Methylamino)azetidin-1-yl]-N⁴-propylpyrimidine-2,4-diamine,
 N⁴-(2,2-Dimethylpropyl)-6-[(3R)-3-methylpiperazin-1-yl]pyrimidine-2,4-diamine,
 N⁴-Ethyl-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine,
 N⁴-(Cyclopropylmethyl)-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine,
 6-[3-(Methylamino)azetidin-1-yl]-N⁴-(2-methylbutyl)pyrimidine-2,4-diamine,
 20 N⁴-Butyl-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine,
 6-[(3R)-3-(Methylamino)pyrrolidin-1-yl]-N⁴-(2-methylcyclopropyl)pyrimidine-2,4-
 diamine,
 N⁴-Isobutyl-6-(4-methyl-1,4-diazepan-1-yl)pyrimidine-2,4-diamine,
 N⁴-(Cyclopropylmethyl)-6-(3-pyrrolidin-1-ylazetidin-1-yl)pyrimidine-2,4-diamine,
 25 N⁴-Bicyclo[1.1.1]pent-1-yl-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-
 diamine,
 6-[3-Methyl-3-(methylamino)azetidin-1-yl]-N⁴-propylpyrimidine-2,4-diamine,
 N⁴-(2,2-Dimethylpropyl)-6-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)pyrimidine-2,4-
 -diamine,
 30 N⁴-(2,2-Dimethylpropyl)-6-(3-pyrrolidin-1-ylazetidin-1-yl)pyrimidine-2,4-diamine,
 N⁴-(2,2-Dimethylpropyl)-6-[3-(isopropylamino)azetidin-1-yl]pyrimidine-2,4-diamine,
 N⁴-(*tert*-Butyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine,
 6-[(3R)-3-(Methylamino)pyrrolidin-1-yl]-N⁴-(1-methylcyclopropyl)pyrimidine-2,4-
 diamine,
 35 N⁴-(*tert*-Butyl)-6-[(4aS*,7aS*)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-
 2,4-diamine,
 N⁴-(2,2-Dimethylpropyl)-6-piperazin-1-ylpyrimidine-2,4-diamine,
 N⁴-(2,2-Dimethylpropyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidine-2,4-diamine
 hydrochloride,


- N^4 -(2,2-Dimethylpropyl)-6-[(3aR*,7aS*)-octahydro-5H-pyrrolo[3,2-c]pyridin-5-yl]-pyrimidine-2,4-diamine,
 6-Piperazin-1-yl- N^4 -propylpyrimidine-2,4-diamine,
 N^4 -(Cyclopropylmethyl)-6-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-pyrimidine-2,4-diamine,
 5 N^4 -(2,2-Dimethylpropyl)-6-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-pyrimidine-2,4-diamine,
 N^4 -(Cyclopropylmethyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine,
 10 N^4 -Isopropyl-6-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine,
 4-[3-(Methylamino)azetidin-1-yl]-6-(4-methylpiperidin-1-yl)pyrimidin-2-amine,
 N^4 -(Cyclopentylmethyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine,
 15 N^4 -Cyclobutyl-6-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidine-2,4-diamine,
 6-[(3R)-3-(Methylamino)pyrrolidin-1-yl]- N^4 -propylpyrimidine-2,4-diamine, and
 N^4 -Ethyl-6-(4-methyl-1,4-diazepan-1-yl)pyrimidine-2,4-diamine.
- 20 12. A compound according to claim 1, or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof, which is:
 N^4 -(Cyclopropylmethyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine.
- 25 13. A pharmaceutically and/or veterinarily acceptable salt according to claim 1, which is:
 N^4 -(Cyclopropylmethyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine tartrate.
- 30 14. A pharmaceutical composition including a compound according to any of claims 1 to 13, or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof, together with a pharmaceutically acceptable excipient.
- 35 15. A compound according to any of claims 1 to 13 or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof, for use as a medicament.
16. The use of a compound according to any of claims 1 to 13 or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof, for the manufacture of a medicament to treat a disease for which a H_4 ligand is indicated.

17. The use according to claim 16, for the manufacture of a medicament to treat a disease selected from inflammatory diseases, respiratory diseases (e.g. adult respiratory distress syndrome, acute respiratory distress syndrome, bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, asthma, emphysema, rhinitis, chronic sinusitis), allergy; allergy-induced airway responses, allergic rhinitis, viral rhinitis, non-allergic rhinitis, perennial and seasonal rhinitis, nasal congestion, allergic congestion, female and male sexual dysfunction, skin diseases such as dermatitis and psoriasis, cardiac dysfunctions such as myocardial ischaemia and arrhythmia, diseases of the gastrointestinal tract such as inflammatory bowel disease, Crohn's disease and colitis ulcerosa, cancer, rheumatoid arthritis, hypotension, pain and overactive bladder conditions.


18. A method of treatment of a mammal, including a human being, suffering from a disease for which a H_4 ligand is indicated, comprising administering to said mammal an effective amount of a compound according to any of claims 1 to 13.

19. A process for preparing a compound according to any of claims 1 to 13, comprising the steps of:

20 (a) reacting a compound of Formula (III)




with an amine $HN(R^1)(R^4)$ to provide a compound of formula (II)




followed by reaction with an amine $HN(R^2)(R^3)$ to provide a compound of formula (I); or

25 (b) reacting a compound of formula (III)



with an amine $\text{HN}(\text{R}^2)(\text{R}^3)$ to provide a compound of formula (IV)



followed by reaction with an amine $\text{HN}(\text{R}^1)(\text{R}^4)$ to provide a compound of formula (I);

- 5 wherein R^1 , R^2 , R^3 , R^4 , R^5 and R^8 are as defined in claim 1, and X and Y are leaving groups.

20. Combination of a compound according to any one of claims 1 to 13, or a pharmaceutically acceptable salt or solvate thereof, with other therapeutic agent(s)
10 selected from:

- Histamine H_1 receptor antagonists, in particular loratidine, desloratidine, fexofenadine and cetirizine
- Histamine H_3 receptor antagonists
- Histamine H_2 receptor antagonists
- 15 • Leukotriene antagonists, including antagonists of LTB_4 , LTC_4 , LTD_4 , and LTE_4 ; for example Montelukast
- Phosphodiesterase inhibitors, including PDE3 inhibitors, PDE4 inhibitors, PDE5 inhibitors, PDE7 inhibitors and inhibitors of two or more phosphodiesterases, such as dual PDE3/PDE4 inhibitors
- 20 • neurotransmitter re-uptake inhibitors, in particular fluoxetine, setraline, paroxetine, ziprasidone
- 5-Lipoxygenase (5-LO) inhibitors or 5-lipoxygenase activating protein (FLAP) antagonists
- α_1 - and α_2 -adrenoceptor agonist vasoconstrictor sympathomimetic agents for
25 decongestant use
- Muscarinic M3 receptor antagonists or anticholinergic agents
- β_2 -adrenoceptor agonists
- Dual acting $\beta_2/\text{M}3$ agents

- Xanthines, such as theophylline and aminophylline
- Non-steroidal anti-inflammatories, such as sodium cromoglycate and nedocromil sodium
- Ketotifen
- 5 • COX-1 inhibitors (NSAIDs) and COX-2 selective inhibitors
- Oral or inhaled Glucocorticosteroids
- Monoclonal antibodies active against endogenous inflammatory entities
- Anti-tumor necrosis factor (anti-TNF- α) agents
- Adhesion molecule inhibitors including VLA-4 antagonists
- 10 • Kinin-B₁ - and B₂ -receptor antagonists
- Immunosuppressive agents
- Inhibitors of matrix metalloproteases (MMPs)
- Tachykinin NK₁, NK₂ and NK₃ receptor antagonists
- Elastase inhibitors
- 15 • Adenosine A2a receptor agonists
- Inhibitors of urokinase
- Compounds that act on dopamine receptors, e.g. D2 agonists
- Modulators of the NF κ B pathway, e.g. IKK inhibitors
- Agents that can be classed as mucolytics or anti-tussive
- 20 • Antibiotics
- Modulators of cytokine signalling pathways, such as p38 MAP kinase inhibitors, syk tyrosine kinase inhibitors or JAK kinase inhibitors
- Modulators of the prostaglandin pathways, including inhibitors of H-PDGS and antagonists of DP-1 and CRTH2
- 25 • Antagonists of chemokine receptors CXCR1 and CXCR2
- Antagonists of chemokine receptors CCR3, CCR4 and CCR5
- Inhibitors of cytosolic and soluble phospholipase A₂ (cPLA₂ and sPLA₂)
- Prostaglandin D2 receptor antagonists (DP1 and CRTH2)
- Inhibitors of Prostaglandin D synthase (PGDS)
- 30 • Inhibitors of phosphoinositide-3-kinase,
- HDAC inhibitors,
- p38 inhibitors and/or
- CXCR2 antagonists.